1
|
Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Hopkins JF, Albacker LA, Chelliserry J, Chen Y, Conte U, Wardley AM, Robson ME. Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ Breast Cancer 2023; 9:81. [PMID: 37803017 PMCID: PMC10558443 DOI: 10.1038/s41523-023-00561-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 06/15/2023] [Indexed: 10/08/2023] Open
Abstract
These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib in the open-label, two-cohort, Phase 2 ABRAZO trial in germline BRCA1/2-mutation carriers. In the evaluable intent-to-treat population (N = 60), 58 (97%) patients harbor ≥1 BRCA1/2 mutation(s) in tumor sequencing, with 95% (53/56) concordance between germline and tumor mutations, and 85% (40/47) of evaluable patients have BRCA locus loss of heterozygosity indicating HRD. The most prevalent non-BRCA tumor mutations are TP53 in patients with BRCA1 mutations and PIK3CA in patients with BRCA2 mutations. BRCA1- or BRCA2-mutated tumors show comparable clinical benefit within cohorts. While low patient numbers preclude correlations between HRD and efficacy, germline BRCA1/2 mutation detection from tumor-only sequencing shows high sensitivity and non-BRCA genetic/genomic events do not appear to influence talazoparib sensitivity in the ABRAZO trial.ClinicalTrials.gov identifier: NCT02034916.
Collapse
Affiliation(s)
- Nicholas C Turner
- The Royal Marsden Hospital, The Institute of Cancer Research, London, UK.
| | | | | | - Hope S Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
| | - Audrey Mailliez
- Department of Medical Oncology, Breast Cancer Unit, Centre Oscar Lambret, Lille, France
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Eva-Maria Grischke
- Universitӓts Frauenklinik Tübingen, Eberhard Karls University, Tübingen, Germany
| | - Lida A Mina
- Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | - Judith Balmaña
- Hospital Vall d'Hebron, and Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Peter A Fasching
- University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - Sara A Hurvitz
- University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA, USA
| | | | | | | | | | | | - Andrew M Wardley
- Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - Mark E Robson
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
2
|
Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist 2023; 28:845-855. [PMID: 37318349 PMCID: PMC10546823 DOI: 10.1093/oncolo/oyad139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Accepted: 04/14/2023] [Indexed: 06/16/2023] Open
Abstract
BACKGROUND The undetermined efficacy of the current standard-of-care neoadjuvant treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple-negative breast cancer (TNBC) and germline BRCA mutations emphasizes the need for biomarker-targeted treatment, such as poly(ADP-ribose) polymerase inhibitors, in this setting. This phase II, single-arm, open-label study evaluated the efficacy and safety of neoadjuvant talazoparib in patients with germline BRCA1/2-mutated early-stage TNBC. PATIENTS AND METHODS Patients with germline BRCA1/2-mutated early-stage TNBC received talazoparib 1 mg once daily for 24 weeks (0.75 mg for moderate renal impairment) followed by surgery. The primary endpoint was pathologic complete response (pCR) by independent central review (ICR). Secondary endpoints included residual cancer burden (RCB) by ICR. Safety and tolerability of talazoparib and patient-reported outcomes were assessed. RESULTS Of 61 patients, 48 received ≥80% talazoparib doses, underwent surgery, and were assessed for pCR or progressed before pCR assessment and considered nonresponders. pCR rate was 45.8% (95% confidence interval [CI], 32.0%-60.6%) and 49.2% (95% CI, 36.7%-61.6%) in the evaluable and intent-to-treat (ITT) population, respectively. RCB 0/I rate was 45.8% (95% CI, 29.4%-63.2%) and 50.8% (95% CI, 35.5%-66.0%) in the evaluable and ITT population, respectively. Treatment-related adverse events (TRAE) were reported in 58 (95.1%) patients. Most common grade 3 and 4 TRAEs were anemia (39.3%) and neutropenia (9.8%). There was no clinically meaningful detriment in quality of life. No deaths occurred during the reporting period; 2 deaths due to progressive disease occurred during long-term follow-up (>400 days after first dose). CONCLUSIONS Neoadjuvant talazoparib monotherapy was active despite pCR rates not meeting the prespecified threshold; these rates were comparable to those observed with combination anthracycline- and taxane-based chemotherapy regimens. Talazoparib was generally well tolerated. CLINICALTRIALS.GOV IDENTIFIER NCT03499353.
Collapse
Affiliation(s)
- Jennifer K Litton
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - J Thaddeus Beck
- Department of Medical Oncology and Hematology, Highlands Oncology, Springdale, AR, USA
| | - Jason M Jones
- Avera Medical Group Oncology & Hematology, Avera Cancer Institute, Sioux Falls, SD, USA
| | - Jay Andersen
- Medical Oncology, Compass Oncology, West Cancer Center, US Oncology Network, Tigard, OR, USA
| | - Joanne L Blum
- Department of Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX, USA
| | - Lida A Mina
- Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | - Raymond Brig
- Medical Oncology, Brig Center for Cancer Care and Survivorship, Knoxville, TN, USA
| | - Michael Danso
- Medical Oncology, Virginia Oncology Associates, Norfolk, VA, USA
| | - Yuan Yuan
- Department of Medical Oncology & Therapeutics Research, Cedars-Sinai Cancer Center, West Hollywood, CA, USA
| | | | - Kay Noonan
- Clinical Oncology, Pfizer Inc., Groton, CT, USA
| | | | | | - Akos Czibere
- Oncology Drug Development, Pfizer Inc., Cambridge, MA, USA
| | - William F Symmans
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Melinda L Telli
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
3
|
Batalini F, DaSilva LL, Campoverde L, Comini ACM, Carvalho BM, Nogueira W, Silveira H, Ernst BJ, Mina LA. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Chin Clin Oncol 2023:cco-22-114. [PMID: 37211773 DOI: 10.21037/cco-22-114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
BACKGROUND Mutations in the BRCA1/2 (BRCA) genes are associated with response to poly(ADPribose) polymerase (PARP) inhibitors (PARPi). In addition, there are different homologous recombination deficiency (HRD) biomarkers available in clinical practice [e.g., genome-wide loss-of-heterozygosity (gLOH) and myChoice® score] that identify patients who can benefit from PARPi. Inconsistencies in biomarkers used in PARPi clinical trials make it challenging to identify clinically relevant predictive biomarkers. This study aims to compare clinically available HRD biomarkers in terms of benefits from PARPi. METHODS We performed database search for phase II or III randomized clinical trials comparing PARPi versus chemotherapy, and meta-analysis using generic inverse variance and a Random Effects model. Patients were classified according to their HRD status: (I) BRCAm (patients with BRCA mutation of germline or somatic origin); (II) non-BRCA HRD [patients BRCA wild-type (wt) with another HRD biomarker-gLOH or myChoice®]; and (III) homologous recombination proficiency (HRP) (BRCAwt and without HRD biomarkers). From those that were BRCAwt, we compared myChoice®+ with gLOH-high. RESULTS Five studies (3,225 patients) analyzing PARPi in first line setting were included. Patients with BRCAmut had progression-free survival (PFS) with hazard ratio (HR) 0.33 [95% confidence interval (CI): 0.30-0.43]; patients with non-BRCA HRD had a PFS HR 0.49 (95% CI: 0.37-0.65), and patients with HRP had a PFS HR 0.78 (95% CI: 0.58-1.03). Eight studies (5,529 patients) with PARPi including first line and recurrence settings were included. BRCAmut had PFS HR 0.37 (95% CI: 0.30-0.48), BRCAwt & HRD 0.45 (95% CI: 0.37-0.55) and HRP 0.70 (95% CI: 0.57-0.85). Patients with BRCAwt & myChoice® ?42 had PFS HR 0.43 (95% CI: 0.34-0.56), similar to patients with BRCAwt & gLOH-high with PFS HR 0.42 (95% CI: 0.28-0.62). CONCLUSIONS Patients with HRD derived significantly more benefit from PARPi when compared to patients with HRP. The benefit of PARPi in patients with HRP tumors was limited. Careful cost-effectiveness analysis, and alternative therapies or clinical trial enrollment should strongly be considered for patients with HRP tumors. Among patients with BRCAwt, a similar benefit was found in patients with gLOH-high and those myChoice®+. The clinical development of further HRD biomarkers (e.g., Sig3) may help identify more patients who benefit from PARPi.
Collapse
Affiliation(s)
- Felipe Batalini
- Department of Clinical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA; Department of Clinical Oncology, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | | - Brenda J Ernst
- Department of Clinical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
| | - Lida A Mina
- Department of Clinical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
| |
Collapse
|
4
|
Batalini F, Mina LA, Mina A. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter. Clin Cancer Res 2023; 29:1157. [PMID: 36916193 DOI: 10.1158/1078-0432.ccr-22-3510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 12/21/2022] [Accepted: 01/25/2023] [Indexed: 03/15/2023]
|
5
|
Jahan N, Taraba J, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, Cathcart-Rake E, O’Sullivan CC, Peethambaram P, Hobday TJ, Ruddy K, Mina LA, Advani P, Batalini F, Goetz MP, Haddad TC, Couch FJ, Yadav S. Abstract P4-01-22: Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p4-01-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Two poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) are currently FDA-approved for the treatment of HER2-negative metastatic breast cancer (MBC) in carriers of germline pathogenic variants (PVs) in BRCA1 or BRCA2 (BRCA1/2). This study explores the clinical outcomes of MBC patients treated with a PARPi. Methods: In this retrospective study, we included MBC patients treated with a PARPi between January 2017 and February 2022 at Mayo Clinic (Minnesota, Arizona, Florida, and Mayo Clinic Health Systems). We used the Kaplan Meier method to estimate the time-to-treatment-failure (TTF) and the log-rank test to compare different subsets. In addition, predictors of TTF were identified in a multivariate cox-proportional hazard regression model, including age at PARPi initiation, race, ethnicity, histology, estrogen receptor (ER), progesterone receptor (PR), and HER2 expression of the tumor, the number of prior therapies, type of PARPi, and PV carrier status (germline BRCA1/2 or PALB2 vs. somatic BRCA1/2 vs. other). Results: Sixty-five patients treated with PARPi (olaparib: 51; talazoparib: 14) were included in the final analysis. Fifty-five patients were carriers of germline PVs in BRCA1 (n=24, 37%), BRCA2 (n=27, 42%) or PALB2 (n=4, 6%), whereas ten patients (15%) had no germline PVs but the tumor had a somatic mutation in the homologous recombination-related (HRR) genes (7 in BRCA1/2, 2 in ATM, and 1 in CDKN2A and CDH1). At the data cutoff, 48 (74%) patients had discontinued PARPi due to progression or death. Fifteen (23%) patients required a dose reduction due to side effects. Occurrence of grade ≥ 3 side effects: anemia in 8, fatigue in 4, neutropenia in 2, and thrombocytopenia in 2 patients. Eight (15.7%) patients in the olaparib group and seven (50%) patients in the talazoparib group required a dose reduction for side effects. No patient on olaparib required drug discontinuation due to side effects, whereas two patients on talazoparib were switched to olaparib due to cytopenias and could tolerate olaparib. Median TTF in the overall population was 8 months (95% confidence interval [CI]: 6.4 – 9.6), and there was no difference (p=0.64) in TTF between the olaparib and talazoparib groups. Median TTF in the germline BRCA1, BRCA2, and PALB2 PV carriers were 7, 8, and 11 months, respectively (p=0.57). Among patients with somatic BRCA1/2 mutations, the median TTF was 4 months. Numerically, patients with HER2-positive tumors (n=8) had a shorter TTF compared to HER2-negative tumors (Median TTF: 4 vs. 8 months, p=0.098). No significant difference in TTF was observed by ER or PR status of the tumor, age at initiation of PARPi, the number of prior therapies, and prior use of platinum-based chemotherapy or CDK4/6 inhibitors. In multivariate analysis, HER2 positivity (hazard ratio [HR]: 8.0, 95% CI: 2.2 – 29.4, p=0.002), somatic BRCA1/2 mutations (HR: 7.6, 95% CI: 1.2 – 50.0, p=0.03) and somatic mutations in other HRR genes (HR: 19.1, 95% CI: 3.1 – 118.6, p=0.002) were associated with worse TTF. Conclusions: In the real world, PARPi were well-tolerated with promising time-to-treatment-failure (TTF) benefits comparable to data from clinical trials. Notably, relatively shorter TTF was observed in patients with somatic BRCA1/2 and other HRR gene mutations and HER2-positive MBC. These findings improve our understanding of the role of PARPi in MBC and will help to guide treatment decisions with PARPi in the clinical setting.
Citation Format: Nusrat Jahan, Jodi Taraba, Karthik V. Giridhar, Roberto A. Leon-Ferre, Amye J. Tevaarwerk, Elizabeth Cathcart-Rake, Ciara C. O’Sullivan, Prema Peethambaram, Timothy J. Hobday, Kathryn Ruddy, Lida A. Mina, Pooja Advani, Felipe Batalini, Matthew P. Goetz, Tufia C. Haddad, Fergus J. Couch, Siddhartha Yadav. Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-01-22.
Collapse
|
6
|
Campoverde L, Lopes Da Silva L, Silveira H, Coelho Nogueira W, Mina LA, Lopes G, Batalini F. Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e17615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17615 Background: Germline BRCA1/2 mutations are associated with response to Poly(ADP-ribose) polymerase inhibitors (PARPi). In addition to BRCA1/2 mutations, there are other Homologous Recombinations Deficiency (HRD) biomarker candidates already available in clinical practice including genome-wide loss-of-heterozygosity (gLOH) and myChoice score. Inconsistencies in biomarkers used in clinical trials with PARPi are a challenge to clinical interpretation. This study aims to compare clinically available HRD biomarkers in terms of benefits from PARPi. Methods: We performed database search for phase II or III randomized clinical trials comparing PARPi versus chemotherapy, and meta-analysis using generic inverse variance and a random-effects model. Patients were classified into three categories according to their HRD status: 1) BRCAmut (patients with BRCA1/2 mutation of germline or somatic origin), 2) non-BRCA HRD (patients BRCA wild-type (wt) with a different HRD biomarker - gLOH or myChoice); and 3) homologous recombination proficiency (HRP) (BRCAwt and without HRD biomarkers). From those that were BRCAwt, we compared myChoice+ with gLOH-high. Results: Eight studies (n = 4372 patients) with PARPi as first-line and recurrence settings were included. BRCAmut had PFS HR 0.29 (95%CI, 0.24-0.35), BRCAwt & HRD 0.43 (95%CI, 0.34-0.53) and HRP 0.74 (95%CI, 0.62-0.89). In a secondary analysis by HRD stratification method, patients with BRCAwt & myChoice > = 42 had PFS HR 0.43 (95%CI, 0.34-0.56), similar to patients with BRCAwt & gLOH-high with PFS HR 0.42 (95%CI, 0.28-0.62). Conclusions: Patients with BRCA mutations benefited the most from PARPi. From patients with BRCA1/2 wild-type, a similar benefit was found in patients with gLOH-high and those myChoice+, which was superior to HRP patients. The clinical development of further HRD biomarkers (i.e. Sig3, HRDetect) may help identify more patients who benefit from PARPi.
Collapse
Affiliation(s)
- Leticia Campoverde
- University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, FL
| | | | | | | | | | - Gilberto Lopes
- University of Miami Miller School of Medicine, Miami, FL
| | | |
Collapse
|
7
|
Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res 2022; 28:1383-1390. [PMID: 35091441 PMCID: PMC9365365 DOI: 10.1158/1078-0432.ccr-21-2080] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 10/18/2021] [Accepted: 01/25/2022] [Indexed: 01/07/2023]
Abstract
PURPOSE PARP inhibitors (PARPi) have demonstrated efficacy in tumors with germline breast cancer susceptibility genes (gBRCA) 1 and 2 mutations, but further factors influencing response to PARPi are poorly understood. EXPERIMENTAL DESIGN Breast cancer tumor tissue from patients with gBRCA1/2 mutations from the phase III EMBRACA trial of the PARPi talazoparib versus chemotherapy was sequenced using FoundationOne CDx. RESULTS In the evaluable intent-to-treat population, 96.1% (296/308) had ≥1 tumor BRCA (tBRCA) mutation and there was strong concordance (95.3%) between tBRCA and gBRCA mutational status. Genetic/genomic characteristics including BRCA loss of heterozygosity (LOH; identified in 82.6% of evaluable patients), DNA damage response (DDR) gene mutational burden, and tumor homologous recombination deficiency [assessed by genomic LOH (gLOH)] demonstrated no association with talazoparib efficacy. CONCLUSIONS Overall, BRCA LOH status, DDR gene mutational burden, and gLOH were not associated with talazoparib efficacy; however, these conclusions are qualified by population heterogeneity and low patient numbers in some subgroups. Further investigation in larger patient populations is warranted.
Collapse
Affiliation(s)
- Joanne L. Blum
- Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, Texas.,Corresponding Author: Joanne L. Blum, Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, 3410 Worth Street, Suite 400, Dallas, TX 75246. Phone: 214-370-1050; E-mail:
| | | | | | - Hope S. Rugo
- University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Sara A. Hurvitz
- University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
| | - Henri H. Roché
- Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - Kyung-Hun Lee
- Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | | | | | | | | | | | | | | | - Lida A. Mina
- Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Gilbert, Arizona
| |
Collapse
|
8
|
Beeram M, Wang JS, Mina LA, Chalasani P, Shatsky RA, Wesolowski R, Hurvitz SA, Trivedi MS, Han HS, Patnaik A, Huynh MM, Jayanthan A, Pambid MR, Yue L, Los G, Dunn SE, Dorr A. Abstract P5-17-12: First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p5-17-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Durably effective therapeutic options remain elusive for metastatic triple negative breast cancer (mTNBC) patients. RSK is a novel target kinase for mTNBC, given its integral role in the MAPK/PDK-1 pathways. PMD-026, uniquely developed for TNBC, is a first-in-class, potent, oral RSK inhibitor that constitutes a promising avenue of treatment for mTNBC. PMD-026 demonstrated a favorable safety profile and initial signs of clinical benefit in metastatic breast cancer patients in Phase I. The current expansion is investigating PMD-026 in mTNBC patients whose disease has progressed on standard therapy. Methods: This open-label study evaluates the safety and efficacy of single agent PMD-026 in mTNBC patients. Target accrual for this study is a minimum of 20 mTNBC patients dosed at 200 mg q 12 hours who have measurable disease. A food effect (FE) sub-study is enrolling a total of 12 patients with a two-arm crossover design. Exploratory biomarker analysis of tumor tissue is being assessed for activated RSK2 levels. Exploratory objectives are to understand TNBC heterogeneity, with a view to identify patients who may benefit from PMD-026 optimally. Results: Based on the trial results thus far from 25 patients, PMD-026 continues to be well-tolerated with no G4 treatment-related adverse events. The noted toxicities include low incidence of elevated ALT/AST, rash, colitis or low-grade nausea. There has been no hair loss, myelosuppression or peripheral neuropathy. Given that TNBC is such a heterogeneous disease, we sought to identify subsets of patients with extensive prior therapy (≥ 5 lines) who may benefit from PMD-026 as a monotherapy. Based on ongoing analyses in the Phase I and Ib, patients diagnosed with TNBC at their initial diagnosis (de novo TNBC) stayed on study 3-4 times longer than patients who were initially treated for HR+ or HER2+ breast cancer but lost HR or HER2 expression to become TNBC (secondary TNBC). In addition, de novo TNBC patients treated at the recommended phase II dose (RP2D) of 200 mg BID with an H score for RSK2 ≥ 180 had a median progression free survival (PFS) of 3.3 months (n=3). In contrast, patients with an H score < 180 had a median PFS of 0 months (n=3). Furthermore, the PFS of 3.3 months on PMD-026 is longer than the PFS of 1.7 months in a similar population of TNBC patients on chemotherapy, where the average number of prior treatments was 3a. . Conclusions: Updated safety, clinical activity, PK, and biomarker analyses will be presented. Clinical trial information: NCT04115306.aBardia et al, N Engl J Med 2021; 384:1529-154
Citation Format: Muralidhar Beeram, Judy S. Wang, Lida A. Mina, Pavani Chalasani, Rebecca A. Shatsky, Robert Wesolowski, Sara A. Hurvitz, Meghna S. Trivedi, Hyo S. Han, Amita Patnaik, My-my Huynh, Aarthi Jayanthan, Mary Rose Pambid, Lambert Yue, Gerrit Los, Sandra E. Dunn, Andrew Dorr. First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-17-12.
Collapse
Affiliation(s)
| | - Judy S. Wang
- Johns Hopkins Medical Institutions, Baltimore, MD
| | | | | | | | - Robert Wesolowski
- The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
| | - Sara A. Hurvitz
- David Geffen School of Medicine, University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA
| | | | | | | | - My-my Huynh
- Phoenix Molecular Designs, Vancouver, BC, Canada
| | | | | | - Lambert Yue
- Phoenix Molecular Designs, Vancouver, BC, Canada
| | - Gerrit Los
- Phoenix Molecular Designs, San Diego, CA
| | | | | |
Collapse
|
9
|
Rugo HS, Blum JL, Laird AD, Hurvitz SA, Ettl J, Mina LA, Lee KH, Gonçalves A, Yerushalmi R, Im YH, Martin M, Fehrenbacher L, Roché HH, Chen Y, Lanzalone S, Chelliserry J, Eiermann W, Litton JK. Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p5-13-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Loss-of-function mutations in genes encoding components of the homologous recombination DNA damage response (DDR) machinery, notably BRCA1/2, are associated with tumor sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi). In EMBRACA, the PARPi TALA improved progression-free survival (PFS) (HR [95% CI] 0.54 [0.41-0.71], P<0.001) vs chemotherapy (CT) in germline BRCA-mutated (gBRCAm) HER2− advanced breast cancer. BRCA1/2 deficiency is associated with elevated PD-L1 expression in ovarian cancers, and PARP inhibition has been associated with PD-L1 upregulation in nonclinical models (Stewart et al, Cancer Res 2018;78:6717-25). Little is known about the potential for PD-L1 expression to modulate sensitivity to PARPi monotherapy in the clinic. Recently, a neoadjuvant study of olaparib in unselected, primary triple-negative breast cancer (TNBC), demonstrated a significant correlation between PD-L1 expression (using the 22C3 antibody) and response to olaparib (Eikesdal et al, Ann Oncol 2021;32:240-9). In contrast, this EMBRACA analysis assessed the contribution of PD-L1 status to TALA sensitivity in a uniformly gBRCAm patient (pt) population. Methods: Available baseline tumor tissue blocks from 120 of 431 EMBRACA pts (28% of intent-to-treat) were sectioned and slides immunostained using SP142/Ventana anti-PD-L1 at HistoGeneX (Naperville, Illinois). PD-L1 immunohistochemistry (IHC) status was assessed as the proportion of tumor area occupied by PD-L1 stained immune cells (IC) of any intensity, with ≥1% defined as PD-L1+. The overall response rate (ORR), defined as unconfirmed complete or partial response (CR/PR), was assessed by investigators. PFS was assessed by an Independent Review Facility. Results: 92/120 (77%) tumors were evaluable for PD-L1 IHC status. Of these 92 evaluable tumors, 9/36 (25%) TNBC and 15/56 (27%) hormone receptor-positive (HR+) tumors were PD-L1+ (24/92, 26% combined TNBC and HR+). In the TALA arm, the ORR was similar for PD-L1+ and PD-L1− tumors for TNBC pts: 2/5 (40%) and 6/19 (32%), respectively. In contrast, the ORR was higher for PD-L1+ vs PD-L1− tumors for HR+ pts: 11/12 (92%) vs 12/31 (39%), exact P value=0.002 (for combined TNBC and HR+, 13/17 [76%] vs 18/50 [36%], P=0.005). For the CT arm, the limited numbers evaluable for both PD-L1 and response (n=25 total), with only one response, precluded similar analysis. Based on the imbalanced results in ORR according to PD-L1 status in pts with HR+ disease, Cox regression analysis was used to explore potential associations of PD-L1 status with PFS. In the TALA arm, median PFS was similar for TNBC independent of PD-L1 status (6.3 mo and 7.0 mo, respectively; HR [95% CI] 1.207 [0.371-3.929]). Median PFS was numerically longer for PD-L1+ vs PD-L1− for HR+ tumors; this difference was not significant (20.2 mo vs 9.2 mo; HR [95% CI] 1.154 [0.395-3.367]). In the CT arm, PD-L1 status was not associated with PFS, although the PD-L1 subgroups were small (For HR+: PD-L1+, n=3; PD-L1−, n=10). Conclusions: Based on these exploratory, retrospective subgroup analyses, PD-L1 positivity by SP142/Ventana was lower in EMBRACA than previously reported in TNBC using the same scoring algorithm: 24/92 (26%) vs 369/902 (41%) in IMpassion130 (Schmid et al, Lancet Oncol 2020;21:44-59). PD-L1+ status was associated with higher ORR in HR+ EMBRACA pts receiving TALA. Interestingly, the enhanced responsiveness for PD-L1+ was not associated with improved PFS, although this assessment is complicated by low pt numbers. Further research is warranted to explore the relationship between baseline tumor PD-L1 status and sensitivity to PARPi, particularly in light of ongoing clinical studies evaluating combinations of immunotherapy and PARPi.
Citation Format: Hope S. Rugo, Joanne L. Blum, A. Douglas Laird, Sara A. Hurvitz, Johannes Ettl, Lida A. Mina, Kyung-Hun Lee, Anthony Gonçalves, Rinat Yerushalmi, Young-Hyuck Im, Miguel Martin, Louis Fehrenbacher, Henri H. Roché, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Wolfgang Eiermann, Jennifer K. Litton. Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-13-08.
Collapse
Affiliation(s)
- Hope S. Rugo
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - Joanne L. Blum
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX
| | | | - Sara A. Hurvitz
- University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | | | - Kyung-Hun Lee
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of
| | | | - Rinat Yerushalmi
- Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
| | | | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain
| | | | - Henri H. Roché
- Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | | | | | | | | | | |
Collapse
|
10
|
Loving VA, Luiten RC, Siettmann JM, Mina LA. A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected Women. Acad Radiol 2022; 29 Suppl 1:S239-S245. [PMID: 33339730 DOI: 10.1016/j.acra.2020.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 12/07/2020] [Accepted: 12/08/2020] [Indexed: 12/01/2022]
Abstract
RATIONALE AND OBJECTIVES Pathogenic mutations in some genes elevate women's breast cancer risk, necessitating risk-reduction strategies. Unfortunately, women are underscreened for cancer risk, and when identified as potentially high risk, women seldom pursue genetic counseling or testing. To improve cancer risk management, this project determined the feasibility of radiology-operated, proactive, same-day risk assessment and genetic testing programs to diagnose high-risk women undergoing breast imaging. MATERIALS AND METHODS The Comprehensive Assessment, Risk & Education Program launched on June 5, 2019. Data was tracked through July 22, 2020. Women undergoing breast imaging completed questionnaires that calculated Tyrer-Cuzick risk and assessed genetic testing eligibility using National Comprehensive Cancer Network criteria. To encourage eligible women's genetic testing adherence, pretest counseling and saliva sample collection occurred that same day in the imaging center. Samples were tested by a 34-multigene panel. Genetic counselors called women with positive results. Women with negative results or variants of uncertain significance were mailed notifications. Summary statistics were calculated. RESULTS A total of 3345 women completed questionnaires. 1080 (32.3%) met genetic testing criteria. 468/1080 (43.3%) submitted genetic samples, and 416/1080 (38.5%) completed testing. Of 416 completed tests, 269 (64.7%) tested negative, 109 (26.2%) had variants of uncertain significance, and 38 (9.1%) diagnosed pathogenic mutations. 13/38 (34.2%) women with pathogenic mutations implemented risk-reduction strategies at our institution. CONCLUSION Breast imaging centers can operate same-day cancer risk assessment and genetic testing programs, identifying high-risk women that conventional risk assessment methods may not have diagnosed. These proactive programs add value to radiology departments' cancer care beyond traditional imaging services.
Collapse
Affiliation(s)
- Vilert A Loving
- Banner MD Anderson Cancer Center, Division of Diagnostic Imaging, Gilbert, Arizona (V.A.L.).
| | - Rebecca C Luiten
- Banner MD Anderson Cancer Center, Division of Cancer Medicine, Gilbert, Arizona (R.C.L., J.M.S., L.A.M.)
| | - Jennifer M Siettmann
- Banner MD Anderson Cancer Center, Division of Cancer Medicine, Gilbert, Arizona (R.C.L., J.M.S., L.A.M.)
| | - Lida A Mina
- Banner MD Anderson Cancer Center, Division of Cancer Medicine, Gilbert, Arizona (R.C.L., J.M.S., L.A.M.)
| |
Collapse
|
11
|
Siettmann JM, Arun B, Gasparini J, Mina LA. Personalized Breast Cancer Risk Assessment: Incorporation of Genetic and High-Risk Factorson Breast Cancer Risk and Management. Chirurgia (Bucur) 2021; 116:S22-S34. [PMID: 34967308 DOI: 10.21614/chirurgia.116.5.suppl.s22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2021] [Indexed: 11/23/2022]
Abstract
Breast cancer remains the second most diagnosed cancer in women worldwide and the number one cause of cancer in women in the United States. It is unfortunately the primary cause of cancerrelated deaths among women, with 14% of all cancer deaths attributed to it. Over the past decade, screening methods have matured, and imaging modalities are continuously improving. Screening mammograms remain the only modality that have been shown to improve breast cancer survival, however, more modalities like MRI, abbreviated MRI, and CT mammography are gaining in momentum. Now more than ever, providers need to identify the patient population that is at an elevated risk for breast cancer to offer them a personalized screening approach specific to their empiric risk. In this paper we shed light on risk factors of breast cancer and summarize risk assessment tools that have been recently incorporated in assessing a woman's risk of breast cancer. We also summarize new genetic testing strategies and their implications in prevention of breast cancer. And finally, we offer a personalized approach to management of women with agenetic predisposition as well as to women at elevated risk but without a genetic mutation. The hope is to identify women at increased risk and perfect a "personalized screening approach" for breast cancer.
Collapse
|
12
|
Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso MA, Yuan Y, Abbattista A, Noonan K, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.505] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
505 Background: Talazoparib (TALA) is a poly(ADP-ribose) polymerase inhibitor approved as monotherapy for treating adult patients (pts) with g BRCA1/2-mutated HER2-negative locally advanced or metastatic BC. Methods: This phase 2, non-randomized, single-arm, open-label study (NCT03499353) evaluated the efficacy and safety of TALA in the neoadjuvant setting for pts with early g BRCA1/2-mutated HER2− BC. Primary endpoint was evaluation of pathologic complete response (pCR) as assessed by Independent Central Review (ICR) after completing 24 weeks of neoadjuvant TALA monotherapy 1 mg QD (0.75 mg for moderate renal impairment) followed by surgery. Secondary endpoints included pCR by investigator (INV) and residual cancer burden (RCB) by ICR (RCB: 0 [pCR], I [minimal], II [moderate], III [extensive]). The evaluable population included pts who received at least 80% of the TALA dose prescribed at treatment start and underwent breast surgery and pCR assessment, plus those who progressed before pCR could be assessed. The intent-to-treat (ITT) population included all pts who received at least 1 dose of TALA. Results: Of 61 pts treated with TALA (ITT and safety populations), 48 comprised the evaluable population. All pts had triple-negative BC. 60 pts had adenocarcinoma and 1 had squamous cell histology, with the following staging: I=20, II=27, III=14. Mean age was 44.6 years, mean duration of 4.5 wks since disease onset, mean duration of treatment of 23.3 wks, and mean overall relative dose intensity of 84.5% (ITT population). pCR (assessed by ICR and INV) and RCB (by ICR) for the evaluable and ITT populations are shown in the table below. Ten (16.4%) patients discontinued treatment due to progressive disease. One pt had a disruption of treatment as a result of COVID-19 restrictions, 2 pts for other reasons: to undergo surgery early and consent withdrawal; 9 patients received <80% dose. Treatment-emergent adverse events (AEs) were reported in 98.4% of pts (27.9% grade [G] 1, 23.0% G2, 45.9% G3, 1.6% G4); the most common were fatigue (78.7%; G1 54.1%; G2 21.3%; G3 3.3%), nausea (68.9%; G1 54.1%; G2 13.1%; G3 1.6%), and alopecia (57.4%; G1 54.1%; G2 3.3%). Three (4.9%) pts discontinued treatment due to AEs (G3 anemia [n=2] and G3 vertigo [n=1]) and continued on study. Conclusions: TALA monotherapy in the neoadjuvant setting was active and showed pCR rates comparable to those observed with combination anthracycline and taxane-based chemotherapy regimens and was generally well tolerated. Clinical trial information: NCT03499353. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Jay Andersen
- Compass Oncology, West Cancer Center, Tigard, OR
| | - Joanne Lorraine Blum
- Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX
| | | | - Raymond Brig
- Brig Center for Cancer Care and Survivorship, Knoxville, TN
| | | | - Yuan Yuan
- City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA
| | | | | | | | | | | | | |
Collapse
|
13
|
Beeram M, Chalasani P, Wang JS, Mina LA, Shatsky RA, Trivedi MS, Wesolowski R, Hurvitz SA, Han HS, Patnaik A, Pambid MR, Jayanthan A, Huynh MM, Los G, Dunn SE, Dorr A. First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13043 Background: P90 ribosomal S6 kinase (RSK) is an actionable molecular target against metastatic triple negative breast cancer (mTNBC). RSK is a major convergence point in the integral TNBC signaling pathways, MAPK and PDK-1. PMD-026 is a first-in-class oral RSK inhibitor with high selectivity. The dose escalation portion of this study established the RP2D of PMD-026 as 200 mg Q12. PMD-026 demonstrated good plasma exposure following oral dosing, with a T1/2 of ̃ 6 h (range 4-8 h), and achieved the targeted preclinical efficacious concentrations using a Q12h dosing schedule. PMD-026 also demonstrated a tolerable safety profile and initial signs of efficacy in patients with metastatic breast cancer. The intensity of RSK2 activation ranged from an H Score of 110-268 based on a CLIA companion immunohistochemistry assay. We present initial data from the expansion cohort. Methods: The primary aim of this single-arm, open-label, first-in-human phase 1/1b study is to evaluate the safety of single agent PMD-026 in patients with mTNBC. Secondary endpoints are clinical activity, pharmacokinetics, and correlative biomarker expression on tumor specimens. Patients are dosed at 200 mg twice daily in 21-day cycles. Eligible patients have measurable disease as per RECIST v1.1 and have had disease progression on or after standard of care treatment. Tumor tissue is assessed to retrospectively correlate RSK2 activity by immunohistochemistry (IHC) with clinical outcomes. Pharmacokinetics are assessed along with a food effect (sub-study with n=12). In addition, a pharmacodynamic marker, YB-1 phosphorylation, is being explored in peripheral blood mononuclear cells before and during treatment. Results: As of February 16, 2021, 7 patients with mTNBC (median age 62 years, range 33-74) have been enrolled in the phase 1b Expansion (median of 7 prior lines of therapy). Notable prior therapies in the phase 1b include sacituzumab govitecan (n=4) and atezolizumab/nab-paclitaxel (n=1). Patients in escalation and expansion treated with the RP2D had median progression free survival of 30 vs 99 days for low vs high RSK2 expression, respectively. This cut-off will be further evaluated in the expansion phase of the study. Conclusions: Updated safety, clinical activity, pharmacokinetic, and biomarker analyses will be presented. Target accrual for phase 1b Expansion is a minimum of 20 patients with mTNBC. Clinical trial information: NCT04115306.
Collapse
Affiliation(s)
| | | | - Judy S. Wang
- Johns Hopkins Medical Institutions, Baltimore, MD
| | | | | | | | - Robert Wesolowski
- The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, and Richard J. Solove Research Institute, Columbus, OH
| | - Sara A. Hurvitz
- David Geffen School of Medicine, University of California, Los Angeles/ Jonsson Comprehensive Cancer Center, Los Angeles, CA
| | | | | | | | | | - My-my Huynh
- Phoenix Molecular Designs, Vancouver, BC, Canada
| | - Gerrit Los
- Phoenix Molecular Designs, San Diego, CA
| | | | | |
Collapse
|
14
|
Telli ML, Litton JK, Beck JT, Jones JM, Andersen J, Mina LA, Brig R, Danso MA, Yuan Y, Symmans WF, Abbattista A, Noonan K, Mata M, Laird D, Blum JL. Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (g BRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
554 Background: TALA is a poly(ADP-ribose) polymerase inhibitor approved as monotherapy for adult pts with g BRCA1/2-mutated HER2-negative locally advanced/metastatic BC. We report biomarker analyses from a phase 2, nonrandomized, single-arm, open-label study (NEOTALA; NCT03499353) evaluating the efficacy and safety of TALA in the neoadjuvant setting for pts with early g BRCA1/2-mutated HER2− BC. Efficacy and safety results are presented separately. Methods: The biomarker analysis population was all pts treated with TALA for whom biomarker results are available. To support molecular eligibility, blood was tested using BRCAnalysis CDx (Myriad Genetics). Baseline tumor tissue was retrospectively tested using FoundationOne CDx, with BRCA1/2 zygosity assessed using somatic-germline-zygosity (SGZ; Sun et al. JCO PO, 2018). Germline mutational status of 14 non- BRCA DNA damage response (DDR) genes was retrospectively assessed in baseline saliva samples using Ambry CustomNext-Cancer. Mutations were defined as known/likely pathogenic/deleterious variants, including copy number alterations (CNAs). Association between mutational status of MYC or RAD21 and primary endpoint pathological complete response (pCR) as per Independent Central Review was investigated with logistic regression. Results: Of 52 evaluable tumor samples from 61 treated pts, 39 (75%) and 13 (25%) pts exhibited BRCA1 and BRCA2 mutations, respectively; 1 (2%) pt exhibited mutations in both genes, and 1 (2%) pt had mutations in neither. BRCA loss of heterozygosity (LOH) was seen in 42/43 (98%) evaluable BRCA-mutant tumors. Of 45 pts evaluable centrally for both germline and tumor, 44/45 (98%) pts exhibited the same BRCA mutation in tumor as originally detected in germline, with the remaining pt exhibiting a g BRCA1 mutation, but lacking a tumor BRCA mutation. None of 49 saliva-evaluable pts exhibited non- BRCA germline DDR mutations. TP53 (51 [98%] pts) was the most frequently mutated gene in tumors. MYC and RAD21 (each 14 [27%] pts) were the most frequent CNAs. No evidence of association between mutational status of MYC or RAD21 and pCR was found (odds ratio=0.39, 95% CI 0.12-2.30). Based on a cutoff of ≥16%, genomic LOH was elevated in 24/27 (89%) tumors evaluable for both gLOH and pCR, precluding assessment of the potential association of gLOH high/low status with pCR. Conclusions: Tumor BRCA mutations were evident in nearly all pts in the biomarker analysis population, with BRCA LOH evident in all but 1 BRCA-mutated tumor. No pts had non- BRCA germline DDR gene mutations; tumor TP53 mutations were near-universal. MYC and RAD21 each exhibited CNAs in 27% of tumors, with no association with pCR. These results support the central role of BRCA mutations in tumor pathobiology in this indication. Clinical trial information: NCT03499353.
Collapse
Affiliation(s)
| | | | | | | | - Jay Andersen
- Compass Oncology, West Cancer Center, Tigard, OR
| | | | - Raymond Brig
- Brig Center for Cancer Care and Survivorship, Knoxville, TN
| | | | - Yuan Yuan
- City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA
| | | | | | | | | | | | - Joanne Lorraine Blum
- Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX
| |
Collapse
|
15
|
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020; 31:1526-1535. [PMID: 32828825 PMCID: PMC10649377 DOI: 10.1016/j.annonc.2020.08.2098] [Citation(s) in RCA: 183] [Impact Index Per Article: 45.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 08/05/2020] [Accepted: 08/10/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall survival (OS). PATIENTS AND METHODS This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received talazoparib or physician's choice of chemotherapy. OS was analyzed using stratified HR and log-rank test and prespecified rank-preserving structural failure time model to account for subsequent treatments. RESULTS A total of 431 patients were entered in a randomized study (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). By 30 September 2019, 216 deaths (75.3%) occurred for talazoparib and 108 (75.0%) chemotherapy; median follow-up was 44.9 and 36.8 months, respectively. HR for OS with talazoparib versus chemotherapy was 0.848 (95% CI 0.670-1.073; P = 0.17); median (95% CI) 19.3 months (16.6-22.5 months) versus 19.5 months (17.4-22.4 months). Kaplan-Meier survival percentages (95% CI) for talazoparib versus chemotherapy: month 12, 71% (66% to 76%)/74% (66% to 81%); month 24, 42% (36% to 47%)/38% (30% to 47%); month 36, 27% (22% to 33%)/21% (14% to 29%). Most patients received subsequent treatments: for talazoparib and chemotherapy, 46.3%/41.7% received platinum and 4.5%/32.6% received a poly(ADP-ribose) polymerase (PARP) inhibitor, respectively. Adjusting for subsequent PARP and/or platinum use, HR for OS was 0.756 (95% bootstrap CI 0.503-1.029). Grade 3-4 adverse events occurred in 69.6% (talazoparib) and 64.3% (chemotherapy) patients, consistent with previous reports. Extended follow-up showed significant overall improvement and delay in time to definitive clinically meaningful deterioration in global health status/quality of life and breast symptoms favoring talazoparib versus chemotherapy (P < 0.01 for all), consistent with initial analyses. CONCLUSIONS In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.
Collapse
Affiliation(s)
- J K Litton
- The University of Texas MD Anderson Cancer Center, Houston, USA.
| | - S A Hurvitz
- University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA
| | - L A Mina
- Banner M.D. Anderson Cancer Center, Gilbert, USA
| | - H S Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - K-H Lee
- Seoul National University Hospital, Seoul, South Korea
| | | | - S Diab
- Rocky Mountain Cancer Centers, Littleton, USA
| | - N Woodward
- Mater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Australia
| | - A Goodwin
- Medical Oncology Department, Concord Repatriation General Hospital, Concord, Australia
| | - R Yerushalmi
- Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
| | - H Roché
- Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Y-H Im
- Samsung Medical Center, Seoul, South Korea
| | - W Eiermann
- Interdisziplinäres Onkologisches Zentrum München, Munich, Germany
| | | | - T Usari
- Pfizer Oncology, Milan, Italy
| | | | | | - J L Blum
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, USA
| | - M Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain
| | - J Ettl
- Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
16
|
Hong F, Ma D, Wu K, Mina LA, Luiten RC, Liu Y, Yan H, Green AA. Precise and Programmable Detection of Mutations Using Ultraspecific Riboregulators. Cell 2020; 183:835-836. [PMID: 33125894 PMCID: PMC7599078 DOI: 10.1016/j.cell.2020.10.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Litton JK, Laird AD, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché H, Im YH, Goodwin A, Blum JL, Eiermann W, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Albacker LA, Frampton GM, Mina LA. Abstract CT072: Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2−) advanced breast cancer (ABC) and a germline BRCA1/2 (g BRCA1/2) mutation. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-ct072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Loss-of-function mutations in genes encoding components of the homologous recombination machinery, notably BRCA1/2, are associated with tumor sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. In EMBRACA, the PARP inhibitor talazoparib (TALA) demonstrated a significant improvement in the primary endpoint of progression-free survival (PFS) (HR [95% CI] 0.54 [0.41-0.71], P < 0.001) vs physician's choice of chemotherapy (PCT) in pts with HER2− ABC and a gBRCA1/2 mutation.
Methods: Baseline tumor tissue (primary or metastatic sites) from 308 pts (71%) in the intent-to-treat population was sequenced using the FoundationOne CDx NGS panel. Mutations summarized below were known/likely pathogenic single-nucleotide variants, insertions, deletions, or rearrangements. Additional exploratory computational analyses pertinent to homologous recombination deficiency were performed, including somatic-germline-zygosity (SGZ) and gLOH assessments.
Results: 296/308 (96%) of evaluable pts exhibited ≥1 tumor BRCA mutation, with BRCA1 and BRCA2 mutations mainly mutually exclusive (4/308 [1%] pts had both BRCA1 and BRCA2 mutations). Of 12 pts with no apparent BRCA mutations, 7 exhibited tumor BRCA copy number alterations deemed pathogenic and 2 had BRCA single-nucleotide variants deemed of unknown pathogenicity. 195/236 (83%) BRCA-mutant (BRCAm) pts evaluable for BRCA LOH status were predicted to exhibit BRCA LOH by SGZ analysis. The potential impact of tumor BRCA mutational zygosity on PFS was explored in the TALA arm calculating HR by Cox proportional hazards model, comparing 122 pts with BRCA LOH with 27 pts without BRCA LOH. This analysis demonstrated no difference in PFS [HR (95% CI): 1.152 (0.680-1.951); P = 0.597)]. gLOH scores were variable, but mostly high: median (range), 21.8% (0.0, 52.7) and 20.5% (0.2, 40.5) for TALA and PCT arms, respectively. The potential association of gLOH scores with selected measures of efficacy was explored. Within both arms gLOH was similar in those pts achieving vs pts not achieving clinical benefit as defined by complete response, partial response, or stable disease ≥24 wks per RECIST v.1.1 as determined by investigator (P = 0.976 and 0.492, respectively, using 2-tailed t-test). In both arms, pts with gLOH ≥ median vs gLOH < median exhibited similar PFS: HR (95% CI) 1.247 (0.828-1.879) for TALA; 1.238 (0.693-2.211) for PCT, with HR <1 favoring gLOH ≥ median.
Conclusions: Selection based on gBRCA mutational status is appropriate to identify HER2− ABC pts with potential for clinical benefit with PARP inhibitors, with tumor BRCA zygosity and gLOH not impacting outcome (within the gBRCAm subset). Additional exploratory correlative analyses are ongoing and will be reported.
Citation Format: Jennifer K. Litton, A. Douglas Laird, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri Roché, Young-Hyuck Im, Annabel Goodwin, Joanne L. Blum, Wolfgang Eiermann, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Lee A. Albacker, Garrett M. Frampton, Lida A. Mina. Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2−) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT072.
Collapse
Affiliation(s)
| | | | - Hope S. Rugo
- 3University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Johannes Ettl
- 4Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Sara A. Hurvitz
- 5University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA
| | - Miguel Martin
- 6Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain
| | - Henri Roché
- 7Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | - Annabel Goodwin
- 9Concord Clinical School, University of Sydney, Sydney, NSW, Australia
| | - Joanne L. Blum
- 10Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RG, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Abstract CT071: Talazoparib (TALA) in germlineBRCA1/2(gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial. Tumour Biol 2020. [DOI: 10.1158/1538-7445.am2020-ct071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
19
|
Beeram M, Wang JSZ, Mina LA, Patnaik A, Pambid MR, Jayanthan A, Huynh MM, Dunn SE, Los G, Dorr A. First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.tps1110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS1110 Background: Metastatic triple negative breast cancer (mTNBC) has a poor prognosis with limited durable treatment options. RSK (P90 ribosomal S6 kinase) is a signaling protein at the convergence point of PDK-1 and MAPK signaling pathways. RSK1-3 phosphorylates transcription factors, including Y-box binding protein-1 (YB-1), thereby inducing drug resistance and cancer growth genes. Phosphorylated YB-1 is involved in tumor cell survival, proliferation, and drug resistance. In human breast tumor samples, RSK2 protein is expressed across all breast cancer subtypes (TNBC, ER+ and HER2+) and is associated with poor overall survival. Expression of RSK2 is found in approximately 87% of mTNBC tumors and of those tumors approximately 41% have very high expression of RSK2. PMD-026 is a potent, oral, small molecule RSK inhibitor with high selectivity for RSK2. Preclinical in vivo studies have demonstrated activity both as a single agent and in combination with standard of care therapies. Further, a CAP/CLIA certified IHC method has been developed with Roche to determine tumor expression of RSK2. Methods: This single-arm, open-label, first-in-human, phase I/Ib study evaluates the safety and efficacy of single agent PMD-026 in patients with metastatic breast cancer for whom standard therapies are no longer effective. During dose escalation, the study utilizes an accelerated titration design with single patient cohorts until the occurrence of DLT or Grade 2+ toxicity; then reverts to 3+3 design to define the maximally tolerated dose (MTD) and recommended phase II dose (RP2D). The dose expansion portion will enroll approximately 20 patients with mTNBC. Patients are dosed orally once daily in 21-day cycles with measures to adapt the dosing schedule based on the pharmacokinetic (PK) data, as needed. Tumor tissue is required for all enrolled patients; RSK2 expression will be retrospectively correlated with clinical outcomes. The primary objectives are to determine safety and tolerability of PMD-026, determine the MTD, define a RP2D, and assess anti-tumor activity of PMD-026 in patients with TNBC. Secondary objectives are to evaluate PK, time to response, mTNBC subtyping using NanoString, and duration of response of PMD-026. To date, cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2020. Clinical trial information: NCT04115306 .
Collapse
Affiliation(s)
| | - Judy Sing-Zan Wang
- Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
| | | | | | | | | | - My-my Huynh
- Phoenix Molecular Designs, Vancouver, BC, Canada
| | | | - Gerrit Los
- Phoenix Molecular Designs, San Diego, CA
| | | |
Collapse
|
20
|
Litton JK, Laird D, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roche H, Im YH, Goodwin A, Blum JL, Eiermann W, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Albacker LA, Frampton GM, Mina LA. Exploring impact of mutations in non- BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (g BRCAm) HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.1018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1018 Background: Loss-of-function mutations in genes encoding components of the homologous recombination DNA damage response (DDR) machinery, notably BRCA1/2, are associated with tumor sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi). In EMBRACA, the PARPi TALA showed an improvement in progression-free survival (PFS) (HR [95% CI] 0.54 [0.41-0.71], P < 0.001) vs physician's choice of chemotherapy (PCT) in g BRCAm HER2− ABC. Methods: Baseline tumor tissue from 308 pts (71%; intent-to-treat) was sequenced using the FoundationOne CDx panel. Mutations summarized below were known/likely pathogenic single-nucleotide variants, insertions, deletions, or rearrangements. Best tumor response (BOR) was using RECIST 1.1 by Investigator (confirmation of CR or PR not required). Results: 296/308 (96%) of evaluable pts exhibited ≥1 tumor BRCA mutation, with 7 of the remaining 12 exhibiting BRCA copy number alterations deemed pathogenic. Mutations in other genes implicated in DDR and/or potential sensitization to PARPi were rare, with mutations detected in BARD1, CDK12, FANCG, STAG2 (each 0.3%), ATR, BRD4, FANCC, PALB2, RAD51B (0.6%), ATM, BRIP1 (1.0%), NBN (1.3%), CHEK2, FANCA (1.6%), and ARID1A (2.3%). No association was observed between total number of DDR mutations, including BRCA1/2, and best tumor response (BOR) [odds ratio of 1 vs ≥2 DDR mutations (95% CI): TALA, 0.76 (0.31-1.87), P = 0.55; PCT, 0.98 (0.27-3.51), P = 0.97]. TP53 and PIK3CA were the most commonly mutated non- BRCA genes in BRCAm tumors (52.0 and 10.8%, respectively). TP53 mutations were more prevalent in BRCA1m vs BRCA2m tumors (85.2 vs 24.8%). PIK3CA mutations were more prevalent in BRCA2m vs BRCA1m tumors (15.9 vs 5.2%). With TALA, PFS was significantly shorter in pts with TP53 mutations than without [HR (95% CI) 1.693 (1.186-2.418), P = 0.0033]. A similar, non-significant, trend was evident with PCT [HR (95% CI) 1.439 (0.859-2.411), P = 0.1614]. PIK3CA mutational status had no impact on PFS in either arm. Conclusions: Selection based on g BRCA mutational status is appropriate to identify HER2─ ABC pts with potential for clinical benefit from TALA, with the total number of tumor mutations in BRCA1/2 and other DDR genes not impacting response (within the g BRCAm subset). TP53 mutations were associated with shorter PFS, likely reflecting the worse outcomes observed in g BRCA1m patients. Additional correlative analyses are ongoing. Clinical trial information: NCT01945775 .
Collapse
Affiliation(s)
| | | | - Hope S. Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Sara A. Hurvitz
- University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA
| | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain
| | - Henri Roche
- Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | - Annabel Goodwin
- Concord Clinical School, University of Sydney, NSW, Australia
| | - Joanne Lorraine Blum
- Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Hong F, Ma D, Wu K, Mina LA, Luiten RC, Liu Y, Yan H, Green AA. Precise and Programmable Detection of Mutations Using Ultraspecific Riboregulators. Cell 2020; 180:1018-1032.e16. [PMID: 32109416 PMCID: PMC7063572 DOI: 10.1016/j.cell.2020.02.011] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Revised: 01/01/2020] [Accepted: 02/04/2020] [Indexed: 12/18/2022]
Abstract
The ability to identify single-nucleotide mutations is critical for probing cell biology and for precise detection of disease. However, the small differences in hybridization energy provided by single-base changes makes identification of these mutations challenging in living cells and complex reaction environments. Here, we report a class of de novo-designed prokaryotic riboregulators that provide ultraspecific RNA detection capabilities in vivo and in cell-free transcription-translation reactions. These single-nucleotide-specific programmable riboregulators (SNIPRs) provide over 100-fold differences in gene expression in response to target RNAs differing by a single nucleotide in E. coli and resolve single epitranscriptomic marks in vitro. By exploiting the programmable SNIPR design, we implement an automated design algorithm to develop riboregulators for a range of mutations associated with cancer, drug resistance, and genetic disorders. Integrating SNIPRs with portable paper-based cell-free reactions enables convenient isothermal detection of cancer-associated mutations from clinical samples and identification of Zika strains through unambiguous colorimetric reactions.
Collapse
Affiliation(s)
- Fan Hong
- Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA
| | - Duo Ma
- Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA
| | - Kaiyue Wu
- Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA
| | - Lida A Mina
- Hematology-Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA
| | - Rebecca C Luiten
- Genetics Department, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA
| | - Yan Liu
- Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA
| | - Hao Yan
- Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA.
| | - Alexander A Green
- Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA.
| |
Collapse
|
22
|
Luiten RC, Loving VA, Siettmann J, Reyes B, Mina LA. Abstract P5-08-03: Creation of a high volume, proactive high-risk breast cancer prevention program. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p5-08-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Approximately one out of eight women get breast cancer in their lifetime, and the National Cancer Institute estimates 268,600 new diagnoses in 2019. About 5-10% of breast cancers can be attributed to a genetic predisposition. Identifying women with genetic predispositions is significant because they qualify for more intense breast cancer screening or risk reducing strategies. Unfortunately, genetic testing is often not offered until cancer is diagnosed. This traditional genetic testing model is reactive rather than proactive, and it fails to identify a large proportion of unaffected genetic mutation carriers in the United States.
Purpose: Our goal was to create a proactive system for identifying women at high risk for breast cancer. We integrated an online family history software, Progeny, into our mammography center to screen unaffected women for high-risk status (Tyrer-Cuzick (TC) score ≥ 20%) and National Comprehensive Cancer Network (NCCN) genetic testing criteria.
Methods: Patients undergoing breast imaging were given a computer tablet with a preprogrammed Progeny questionnaire. Progeny collects the patient’s gynecological and family history, calculates a TC risk score, and assesses NCCN genetic testing criteria. Progeny was integrated into the mammography center on 1/10/2019 and this preliminary data was collected through 6/6/2019. Summary statistics were tabulated.
Results: A total of 3,129 patients were invited to complete the questionnaire. 2,474 (79.1%) completed the questionnaire and 540 (21.8%) met NCCN genetic testing criteria. The average age of those meeting NCCN criteria was 60.3 years (range: 21-94). Of the patients who completed the questionnaire, 148 (6.0%) patients were found to be high-risk due to a TC score ≥20%.
Clinical Impact: We found 540 patients who qualified for genetic counseling/testing. Under the previous, reactive genetic testing model, most of these patients would not have been selected for testing unless they received a cancer diagnosis. We recommended pretest genetic counseling to all these high-risk patients. Typical oncology genetic counselors see 10.2 new patients a week and our clinic can see 15 new patients per week. It would take 36 weeks with our current clinic system for all the patients identified during the initial questionnaire trial period to see a genetic counselor for pretest counseling. This demand alone would require two full time genetic counselors to accommodate.
Conclusion: Our initial experience integrating a genetic screening questionnaire into our mammography center shows that 22% of patients need genetic testing and 6% need follow-up in a high-risk breast cancer clinic. Given current staffing constraints, it would take about 9 months to genetic test and counsel the patients identified after just 6 months of screening. This estimate does not include the demand placed on genetic counselors from current referral sources, so actual wait times could be longer than 9 months. This long wait time could increase anxiety for patients and dissatisfaction for patients and providers. A new approach to offering genetic testing and counseling to these patients is needed.
Future Directions: In response to this increased clinical demand, we are partnering with Progeny and Ambry Genetics to create a novel program that allows patients to receive preliminary genetic education by video and genetic testing the same day as their mammogram appointment. Ultimately, the hope is that this new, high volume, proactive high-risk prevention program will allow a larger proportion of women with a genetic predisposition to receive diagnoses of their mutations and to initiate risk reducing and life-saving treatments. With this partnership, we will better accommodate the increased patient demand for genetic testing and avoid long wait times for counseling.
Citation Format: Rebecca C Luiten, Vilert A Loving, Jennifer Siettmann, Beverly Reyes, Lida A Mina. Creation of a high volume, proactive high-risk breast cancer prevention program [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-08-03.
Collapse
Affiliation(s)
| | | | | | | | - Lida A Mina
- Banner MD Anderson Cancer Center, Gilbert, AZ
| |
Collapse
|
23
|
Mina LA, Lim S, Bahadur SW, Firoz AT. Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. Breast Cancer (Dove Med Press) 2019; 11:321-328. [PMID: 32099454 PMCID: PMC6997226 DOI: 10.2147/bctt.s184710] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Accepted: 12/12/2019] [Indexed: 12/12/2022]
Abstract
Breast cancer is the most common type of cancer affecting women in the United States. Triple-negative breast cancer remains the most aggressive molecular subtype secondary to a lack of therapeutic targets. The search for a target has led us to investigate immunotherapeutic agents. Immunotherapy has recently demonstrated significant breakthroughs in various types of cancers that are refractory to traditional therapies including melanoma and Non-Small Cell Lung Cancer (NSCLC). Breast cancer however remains one of the tumors that was initially least investigated because of being considered to have a low immunogenic potential and a low mutational load. Over the past few years, antiPD1/PDL1 drugs have started to make progress in the triple-negative subtype with more promising outcomes. In this report, we review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs in this challenging disease.
Collapse
Affiliation(s)
- Lida A Mina
- Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | - Shannon Lim
- Pharmacy Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | - Shakeela W Bahadur
- Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | - Abdul T Firoz
- Science Department, Arizona State University, Tempe, AZ, USA
| |
Collapse
|
24
|
Hurvitz SA, Gonçalves A, Rugo HS, Lee K, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RG, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist 2019; 25:e439-e450. [PMID: 32162822 PMCID: PMC7066700 DOI: 10.1634/theoncologist.2019-0493] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Accepted: 10/05/2019] [Indexed: 11/17/2022] Open
Abstract
Background In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression‐free survival (PFS) compared with physician's choice of chemotherapy (PCT) in germline BRCA1/2‐mutated HER2‐negative advanced breast cancer (ABC). Herein, the safety profile of talazoparib is explored in detail. Materials and Methods Overall, 412 patients received ≥1 dose of talazoparib (n = 286) or PCT (n = 126). Adverse events (AEs) were evaluated, including timing, duration, and potential overlap of selected AEs. The relationship between talazoparib plasma exposure and grade ≥3 anemia was analyzed. Time‐varying Cox proportional hazard models assessed the impact of dose reductions on PFS. Patient‐reported outcomes (PROs) in patients with common AEs and health resource utilization (HRU) were assessed in both treatment arms. Results The most common AEs with talazoparib were hematologic (195 [68.2%] patients) and typically occurred within the first 3–4 months of receiving talazoparib. Grade 3‐4 anemia lasted approximately 7 days for both arms. Overlapping grade 3‐4 hematologic AEs were infrequent with talazoparib. Higher talazoparib exposure was associated with grade ≥3 anemia. Permanent discontinuation of talazoparib due to hematologic AEs was low (<2%). A total of 150 (52.4%) patients receiving talazoparib had AEs associated with dose reduction. Hematologic toxicities were managed by supportive care medication (including transfusion) and dose modifications. Among patients with anemia or nausea and/or vomiting AEs, PROs favored talazoparib. After accounting for the treatment‐emergent period, talazoparib was generally associated with a lower rate of hospitalization and supportive care medication use compared with chemotherapy. Conclusion Talazoparib was associated with superior efficacy, favorable PROs, and lower HRU rate versus chemotherapy in gBRCA‐mutated ABC. Toxicities were manageable with talazoparib dose modification and supportive care. Implications for Practice Talazoparib was generally well tolerated in patients with germline BRCA‐mutated HER2‐negative advanced breast cancer in the EMBRACA trial. Common toxicities with talazoparib were primarily hematologic and infrequently resulted in permanent drug discontinuation (<2% of patients discontinued talazoparib due to hematologic toxicity). Hematologic toxicities typically occurred during the first 3–4 months of treatment and were managed by dose modifications and supportive care measures. A significant efficacy benefit, improved patient‐reported outcomes, lower rate of health resource utilization and a tolerable safety profile support incorporating talazoparib into routine management of germline BRCA‐mutated locally advanced/metastatic breast cancer. Talazoparib is a viable option for patients with germline BRCA‐mutated advanced breast cancer. This article presents detailed safety analyses for talazoparib, as a follow‐up to reported results from the EMBRACA trial, to highlight patterns of toxicity compared with chemotherapy and to outline guidelines for management of talazoparib toxicity in clinical practice via dose modifications and/or standard supportive care.
Collapse
Affiliation(s)
- Sara A. Hurvitz
- University of California, Los AngelesLos AngelesCaliforniaUSA
| | | | - Hope S. Rugo
- UCSF Helen Diller Family Comprehensive Cancer CenterSan FranciscoCaliforniaUSA
| | | | | | | | - Sami Diab
- Rocky Mountain Cancer CentersLittletonColoradoUSA
| | - Joanne L. Blum
- Baylor Sammons Cancer Center, Texas Oncology, U.S. OncologyDallasTexasUSA
| | | | | | | | | | | | | | | | | | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität MünchenMunichGermany
| |
Collapse
|
25
|
Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr 2019; 4:pkz085. [PMID: 32337496 PMCID: PMC7050154 DOI: 10.1093/jncics/pkz085] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 08/21/2019] [Accepted: 10/08/2019] [Indexed: 11/25/2022] Open
Abstract
Background Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations. Methods EMBRACA (NCT01945775) was a randomized phase III study comparing efficacy, safety, and patient-reported outcomes (PROs) of talazoparib (1 mg) with physician’s choice of chemotherapy (PCT: capecitabine, eribulin, gemcitabine, vinorelbine) in locally advanced or metastatic breast cancer with a germline BRCA1/2 (gBRCA1/2) mutation. Prespecified patient subgroups were analyzed for progression-free survival, objective response, clinical benefit, duration of response, and safety. PROs were evaluated in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) or triple-negative breast cancer (TNBC) subgroups. Results Of 431 patients, 287 were randomly assigned to talazoparib and 144 to PCT. Prespecified subgroup analyses showed prolonged progression-free survival with talazoparib (HR+/HER2−: hazard ratio = 0.47, 95% confidence interval = 0.32 to 0.71; TNBC: hazard ratio = 0.60, 95% confidence interval = 0.41 to 0.87) and greater objective response rate (odds ratio = 1.97 to 11.89), clinical benefit rate (odds ratio = 2.05 to 7.77), and duration of response with talazoparib in all subgroups. PROs in HR+/HER2− and TNBC subgroups showed consistent overall improvement and delay in time to definitive clinically meaningful deterioration with talazoparib vs PCT. Across subgroups, common adverse events included anemia, fatigue, and nausea with talazoparib and neutropenia, fatigue, and nausea with PCT. Seven patients (2.4%) receiving talazoparib had grade II alopecia and 22.7% had grade I alopecia. Conclusions Across all patient subgroups with gBRCA-mutated advanced breast cancer, talazoparib demonstrated clinically significant superiority in outcomes compared with PCT.
Collapse
Affiliation(s)
- Hope S Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Sara A Hurvitz
- University of California, Los Angeles/Jonsson, Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA
| | | | - Kyung-Hun Lee
- Seoul National University Hospital, Seoul, South Korea
| | | | | | - Sami Diab
- Rocky Mountain Cancer Centers, Littleton, CO
| | - Natasha E Woodward
- Mater Cancer Care Centre-Mater Health Services/Mater Research Institute, University of Queensland, South Brisbane, Queensland, Australia
| | | | - Annabel Goodwin
- Concord Repatriation General Hospital, Concord, New South Wales, Australia
| | - Joanne L Blum
- Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX
| | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
26
|
Mina LA, Arun B. Polygenic Risk Scores in Breast Cancer. Curr Breast Cancer Rep 2019. [DOI: 10.1007/s12609-019-00320-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Diab S, Rugo HS, Mina LA, Puhalla S, Mahtani RL, Henry NL, Denduluri N, Yardley DA, Wang Y, Arruda LS, Tudor IC, Gauthier ER, Czibere AG, Litton JK, Hurvitz SA. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.1044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1044 Background: TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2- g BRCAm LA/MBC. Approval was based on results from the Phase 3 EMBRACA trial comparing efficacy/safety of TALA (1 mg/d) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2- g BRCAm LA/MBC pts. This analysis describes outcomes in US pts included in the pivotal study. Methods: Clinical findings from US pts enrolled in EMBRACA were analyzed. Pt characteristics, progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), and safety/adverse events (AEs) were among the parameters assessed. Results: Of 431 randomized pts, 156 pts (36%) were from the US (TALA: 99; PCT: 57). Pt characteristics were balanced, although a higher percentage in the TALA arm had more poor prognostic features (eg, triple-negative breast cancer, disease-free interval < 12 mo, and more disease sites). TALA improved PFS, ORR, CBR, and duration of response (DOR) vs PCT (Table). 22% of pts in the TALA arm had a continued objective response at month 12 vs 0 pts in the PCT arm. The most common AEs in the TALA arm included anemia, neutropenia, thrombocytopenia, fatigue, nausea, alopecia, and headache; hematologic grade 3/4 AEs occurred more often than nonhematologic AEs. Conclusions: In US pts with HER2- g BRCAm LA/MBC, TALA demonstrated significant improvements in outcomes vs PCT with a manageable safety profile. Clinical trial information: NCT01945775. [Table: see text]
Collapse
Affiliation(s)
- Sami Diab
- University of Colorado Cancer Center, Aurora, CO
| | - Hope S. Rugo
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | | | - Shannon Puhalla
- University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Ettl J, Hurvitz SA, Rugo HS, Lee KH, Mina LA, Woodward NE, Yerushalmi R, Diab S, Martin M, Tudor IC, Czibere AG, Gauthier ER, Litton JK, Goncalves A. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.1071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1071 Background: The PARP inhibitor TALA was approved in the US for treatment of g BRCA-mutated ABC based in part on the EMBRACA study. Understanding the outcomes of EMBRACA pts relative to prior CT is a current unmet need. Methods: EMBRACA was a randomized Phase 3 trial comparing TALA 1 mg daily vs PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in g BRCA-mutated ABC. Clinical outcomes were assessed by line of prior CT for ABC in intent-to-treat (ITT), triple-negative breast cancer (TNBC), and hormone receptor-positive (HR+) breast cancer cohorts. Results: 431 pts were randomized (ITT; TALA 287; PCT: 144). TALA was generally more effective than PCT across efficacy endpoints regardless of line of CT (Table). For the ITT population, TALA improved progression-free survival (PFS) and objective response rate (ORR) vs PCT for each line of CT assessed. Other prespecified subgroups (TNBC and HR+) will be presented. Conclusions: In pts with g BRCA-mutated ABC, TALA demonstrated improvements in clinical outcomes compared with PCT regardless of prior lines of CT. Clinical trial information: NCT01945775. [Table: see text]
Collapse
Affiliation(s)
- Johannes Ettl
- Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
| | | | - Hope S. Rugo
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Kyung-Hun Lee
- Seoul National University Hospital, Seoul, South Korea
| | | | - Natasha E. Woodward
- University of Queensland, South Brisbane, Queensland, Australia, South Brisbane, Australia
| | | | - Sami Diab
- University of Colorado Cancer Center, Aurora, CO
| | | | | | | | | | | | | |
Collapse
|
29
|
Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res 2018; 25:2717-2724. [DOI: 10.1158/1078-0432.ccr-18-1891] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 09/18/2018] [Accepted: 12/14/2018] [Indexed: 11/16/2022]
|
30
|
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379:753-763. [PMID: 30110579 PMCID: PMC10600918 DOI: 10.1056/nejmoa1802905] [Citation(s) in RCA: 1215] [Impact Index Per Article: 202.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P=0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).
Collapse
Affiliation(s)
- Jennifer K Litton
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Hope S Rugo
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Johannes Ettl
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Sara A Hurvitz
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Anthony Gonçalves
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Kyung-Hun Lee
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Louis Fehrenbacher
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Rinat Yerushalmi
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Lida A Mina
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Miguel Martin
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Henri Roché
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Young-Hyuck Im
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Ruben G W Quek
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Denka Markova
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Iulia C Tudor
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Alison L Hannah
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Wolfgang Eiermann
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| | - Joanne L Blum
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.)
| |
Collapse
|
31
|
Rugo HS, Ettl J, Woodward NE, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche HH, Im YH, Markova D, Tudor IC, Eiermann W, Blum JL, Hannah AL, Litton JK. EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.1069] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Hope S. Rugo
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | | | | | | | - Kyung-Hun Lee
- Seoul National University Hospital, Seoul, Korea, Republic of (South)
| | | | - Rinat Yerushalmi
- Rabin Medical Center, Beilinson Hospital, Petah Tikva, CA, Israel
| | | | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain
| | - Henri Hubert Roche
- Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - Young-Hyuck Im
- Samsung Medical Center, Seoul, Korea, Republic of (South)
| | | | | | | | | | | | | |
Collapse
|
32
|
Eiermann W, Rugo HS, Diab S, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche HH, Im YH, Markova D, Tudor IC, Blum JL, Hannah AL, Litton JK. Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.1070] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Hope S. Rugo
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Sami Diab
- University of Colorado Cancer Center, Aurora, CO
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | | | | | - Kyung-Hun Lee
- Seoul National University Hospital, Seoul, Korea, Republic of (South)
| | | | - Rinat Yerushalmi
- Rabin Medical Center, Beilinson Hospital, Petah Tikva, CA, Israel
| | | | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain
| | - Henri Hubert Roche
- Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - Young-Hyuck Im
- Samsung Medical Center, Seoul, Korea, Republic of (South)
| | | | | | | | | | | |
Collapse
|
33
|
Hurvitz SA, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Tudor C, Quek RGW, Hannah AL, Robson ME, Wardley AM. Abstract P5-19-05: Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-19-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Talazoparib (TALA; 1 mg/d) was well tolerated and exhibited promising antitumor activity in ABRAZO, a 2-cohort, 2-stage, open-label phase 2 study (NCT02034916) in patients (pts) with locally advanced or metastatic breast cancer and gBRCA1/2 mutations following platinum-based therapy (cohort 1 [C1]) or ≥3 platinum-free cytotoxic-based regimens (cohort 2 [C2]). This analysis evaluates health-related quality of life (QoL) for both cohorts.
Methods: QoL was assessed on day 1 (baseline) and every 6 weeks for the initial 24 weeks and every 12 weeks thereafter, or sooner if progression was clinically suspected, using the EORTC QLQ-C30 and its breast cancer module, QLQ-BR23. For all scales, results were summarized using descriptive statistics for each cohort and at each time point, based on Characters (max 3400 including title, body and table [including spaces]): 3363 No abbreviations in title; title sentence case; define acronyms; no figures Category: Psychosocial, QOL, and Educational Aspects – Other 2 observed values and changes from baseline (clinically meaningful defined as ≥10-point change from baseline). Time to deterioration (TTD; defined as ≥10-point decrease in global health status [GHS]/functional scales or increase in symptom scales) analyses using survival analysis methods were carried out on the GHS/functional scales of QLQ-C30 and symptom scales of QLQ-BR23.
Results:GHS was maintained from baseline across all time points for both C1 and C2 except at week 24 in C2, when a statistically significant but not clinically meaningful improvement in GHS was observed. In C1, statistically significant and clinically meaningful improvement was observed at specific time points in 4 functional scales (body image, week 6; sexual functioning, week 24; sexual enjoyment, week 36; and future perspective, weeks 6, 18, and 24) and in 3 symptom scales (dyspnea, week 24; insomnia, week 24; and breast symptoms, weeks 6 and 36). Statistically significant and clinically meaningful deterioration in C1 was observed in 2 functional scales (emotional functioning, week 12 and end of treatment, and role functioning, end of treatment) and in 1 symptom scale (fatigue, week 6). In C2, statistically significant and clinically meaningful improvement was observed at specific time points in 4 functional scales (role functioning, week 24; social functioning, week 24; sexual enjoyment, week 18; and future perspective, weeks 6, 12, and 18) and in 5 symptom scales (nausea/vomiting, week 18; pain, weeks 12, 18, and 24; insomnia, week 24; breast symptoms, weeks 12 and 18; and arm symptoms, week 48). For C2, no statistically significant and clinically meaningful deterioration was observed for any functional or symptoms scales across all time points, except in the dyspnea symptom scale at week 18. For C1 and C2, the median (95% confidence interval) TTD of GHS was 2.8 (2.1-3.0) and 5.5 (4.2-5.7) months, respectively. The median TTD for all QLQ-C30 functional scales for C1 and C2 ranged 2.1-3.1 and 4.2-5.6 months, respectively; the median TTD for all QLQ-BR23 symptoms scales ranged 2.6-4.0 and 4.2-5.6 months, respectively.
Conclusions: The QoL of TALA-treated patients during ABRAZO was maintained. QoL is being evaluated among atients with germline BRCA1/2 mutated advanced BC treated with TALA vs physician's choice chemotherapy in the phase 3 EMBRACA trial (NCT01945775).
Citation Format: Hurvitz SA, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E-M, Mina LA, Balmaña J, Fasching PA, Tudor C, Quek RGW, Hannah AL, Robson ME, Wardley AM. Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-19-05.
Collapse
Affiliation(s)
- SA Hurvitz
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - NC Turner
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - ML Telli
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - HS Rugo
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - A Mailliez
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - J Ettl
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - E-M Grischke
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - LA Mina
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - J Balmaña
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - PA Fasching
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - C Tudor
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - RGW Quek
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - AL Hannah
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - ME Robson
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| | - AM Wardley
- University of California Los Angeles Health, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Stanford University School of Medicine, Stanford, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom
| |
Collapse
|
34
|
Telli ML, Turner NC, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Hurvitz SA, Wardley AM, Fasching PA, Tudor C, Nguyen L, Hannah AL, Robson ME, Rugo HS. Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-14-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Talazoparib (TALA) is a dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor that traps PARP on DNA. Efficacy results of this phase 2 trial were previously presented (Turner et al, ASCO 2017, abstract 1007). This study included sparse pharmacokinetic (PK) sampling for patients through cycle 4 of therapy. Exploratory analyses included assessment of exposure versus parameters of efficacy and safety.
Methods: ABRAZO (NCT02034916) was a parallel-cohort, open-label phase 2 study of TALA (1 mg/d) following (i) platinum-based therapy (cohort 1) or (ii) ≥3 platinum-free cytotoxic-based regimens (cohort 2) in patients with locally advanced or metastatic breast cancer and germline BRCA1/2 mutation. Sparse PK sampling was performed on day 1 of cycles 1-4, consisting of a predose sample collected ≤60 minutes prior to dosing and 2 postdose samples collected ≥30 minutes after dosing (time of food ingestion prior to the dose was collected). The collection times of the 2 postdose samples were separated by ≥2 hours. Efficacy parameters included radiographic progression-free survival (rPFS) by central review and objective response rate (ORR). Safety parameters included incidence of overall adverse events (AEs) and grade ≥3 AEs. Individual AUCs (area under concentration-time curves) for exposure-response analyses were predicted by population PK analyses.
Results: Patients were divided into AUC tertiles: low (median, 109.0 ng*hr/mL; n=27), intermediate (median, 170.8 ng*hr/mL; n=27), and high (median, 219.2 ng*hr/mL; n=27). Median rPFS was 5.3 months (95% confidence interval [CI], 3.1, 8.3) in the lowest AUC tertile, 5.6 months (95% CI, 3.7, 8.4) in the intermediate AUC tertile, and 5.3 months (95% CI, 3.9, 5.6) in the highest AUC tertile. The ORR was 22.2% (95% CI, 8.6, 42.3) in the lowest AUC tertile, 25.9% (95% CI, 11.1, 46.3) in the intermediate AUC tertile, and 37.0% (95% CI, 19.4, 57.6) in the highest AUC tertile. AEs of any grade were reported in 11 patients (40.7%) in the lowest AUC tertile, 21 patients (77.8%) in the intermediate AUC tertile, and 22 patients (81.5%) in the highest AUC tertile. Grade ≥3 AEs were reported in 8 patients (29.6%) in the lowest AUC tertile and in 18 patients (66.7%) in the intermediate and highest AUC tertiles. The most common AEs in all 3 exposure tertiles were anemia, thrombocytopenia, and neutropenia.
Conclusions: Median rPFS did not change with increasing systemic exposure. There may be a trend to higher ORR in patients with highest systemic exposure. A larger percentage of patients experienced AEs with elevated systemic exposure. Increased response rates with greater exposure does not translate to improved rPFS. These results should be interpreted with caution due to the low patient numbers in each cohort.
Citation Format: Telli ML, Turner NC, Mailliez A, Ettl J, Grischke E-M, Mina LA, Balmaña J, Hurvitz SA, Wardley AM, Fasching PA, Tudor C, Nguyen L, Hannah AL, Robson ME, Rugo HS. ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-14-03.
Collapse
Affiliation(s)
- ML Telli
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - NC Turner
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - A Mailliez
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - J Ettl
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - E-M Grischke
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - LA Mina
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - J Balmaña
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - SA Hurvitz
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - AM Wardley
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - PA Fasching
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - C Tudor
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - L Nguyen
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - AL Hannah
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - ME Robson
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - HS Rugo
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| |
Collapse
|
35
|
Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmana Gelpi J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Verret W, Hannah AL, Robson ME. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.1007] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
1007 Background: TALA is a dual-mechanism PARP inhibitor that traps PARP on DNA. This study was designed to assess the activity of TALA in pts with g BRCA1/2mutation previously exposed to platinum or multiple prior cytotoxic regimens. Methods: ABRAZO (NCT02034916) is a 2-cohort, 2-stage phase 2 study of TALA (1 mg/d) following platinum-based therapy (Cohort 1 [C1]) or ≥ 3 platinum-free cytotoxic-based regimens (Cohort 2 [C2]) in pts with locally advanced or metastatic breast cancer (MBC) and g BRCA1/2mutation. Pts had ECOG PS ≤ 1 and measurable disease by RECIST v1.1. Five responses per cohort were required in ≤ 35 pts to progress to stage 2. The primary endpoint was confirmed ORR by independent radiology facility (IRF). Secondary endpoints: clinical benefit rate ≥ 24 weeks (CBR24), DOR, PFS, and OS. Results: From May 2014 to Feb 2016, 84 pts were enrolled (C1, n = 49; C2, n = 35). At data cutoff (1 Sep 2016), 9 pts continued on treatment. Both cohorts proceeded to stage 2 before enrollment closed. Median age was 50 (range, 31–75) years; 58% of pts had an ECOG PS of 0. TNBC/HR+ incidence in C1 and C2 was 59%/41% and 17%/83%, respectively. Median number of prior cytotoxic regimens administered for advanced disease was 2 in C1 and 4 in C2. ORR by IRF for BRCA1/BRCA2 was 24%/34%, and ORR by IRF for TNBC/HR+ was 26%/29%. Common all grade AEs: anemia (52%), fatigue (45%), nausea (42%), diarrhea (33%), thrombocytopenia (33%), and neutropenia (27%). Grade ≥ 3 AEs: anemia (35%), thrombocytopenia (19%), and neutropenia (15%). Nonhematological AEs grade ≥ 3 did not occur. AEs related to TALA led to drug discontinuation in 3 pts (4%); 4 AEs resulted in death, none related to TALA. Conclusions: TALA was well tolerated in MBC pts with a g BRCA1/2 mutation, exhibiting promising antitumor activity in C1 and C2. TALA vs physician’s choice of treatment in g BRCA1/2-mutated MBC is being evaluated in the phase 3 EMBRACA trial (NCT01945775). Clinical trial information: NCT02034916. [Table: see text]
Collapse
Affiliation(s)
- Nicholas C. Turner
- Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom
| | | | - Hope S. Rugo
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | | | - Johannes Ettl
- Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
| | - Eva-Maria Grischke
- Universitӓts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany
| | | | | | | | - Sara A. Hurvitz
- University of California Los Angeles Health, Santa Monica, CA
| | | | | | | | | | | |
Collapse
|
36
|
Ballinger TJ, Miller K, Ludwig K, Badve SS, Selzer D, Zhang Y, Storniolo AM, Mina LA. Effect of bariatric surgery on breast tissue and biomarkers in obese women at increased risk for breast cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.tps1592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS1592 Background: Obesity represents a challenging epidemic associated with increased risk of several malignancies, including breast cancer in post-menopausal women. Proposed mechanisms for the association between obesity and breast cancer risk include increased insulin resistance, elevated levels of circulating estrogens, and chronic inflammation. Intentional weight loss from bariatric surgery has been associated with decreased risk of breast cancer. While rapid improvements in serologic markers of metabolism and inflammation are seen following bariatric surgery, short- and long- term changes in breast tissue remain less clear. This study investigates the effect of bariatric surgery on breast density and biomarkers of increased risk in breast tissue. Methods: This pilot, single institution, observational study (NCT02681120) is recruiting pre- and post-menopausal women with BMI ≥30 from a University bariatric surgery clinic using the Hughes risk application as a screening tool. Eligible patients must have a lifetime risk for breast cancer of ≥20%. Participants are evaluated by imaging, breast biopsy, and blood samples at baseline, 14 days post-operatively to determine the effects of rapid metabolic changes, and 1 year post-operatively to determine the effects of significant weight loss. The impact of bariatric surgery on known imaging parameters of breast cancer risk is assessed by background parenchymal enhancement on MRI and breast density on mammogram. Breast tissue is evaluated for changes in immune infiltrates, aromatase expression, and the presence of crown-like structures, a marker of inflammation seen in the breast tissue of obese women. Tissue samples at each time point are also compared to samples from lean women in the Susan G. Komen Tissue Bank at the IU Simon Cancer Center. Blood is collected for correlative studies evaluating markers of inflammation, insulin resistance, metabolism, and hormone synthesis. Enrollment is currently ongoing with a planned accrual of 40 patients, and data collection is estimated to complete by the end of 2018. Clinical trial information: NCT02681120.
Collapse
Affiliation(s)
| | - Kathy Miller
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | | | | | - Don Selzer
- Indiana University School of Medicine, Indianapolis, IN
| | - Ying Zhang
- Indiana University School of Medicine, Indianapolis, IN
| | | | | |
Collapse
|
37
|
Litton J, Ettl J, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Yerushalmi R, Woodward N, Goncalves A, Moreno F, Roche H, Im YH, Martin M, Bhattacharya S, Peterson A, Hannah A, Eiermann W, Blum J. Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cancer cells with deleterious mutations in breast cancer susceptibility genes 1 and 2 (BRCA1/2) are deficient in the DNA double-strand break repair mechanism, rendering them highly dependent on the single-strand break repair pathway, regulated by poly(ADP-ribose) polymerase (PARP). Inhibition of PARP results in synthetic lethality in cells with a BRCA1/2 mutation because of accumulation of irreparable DNA damage; PARP inhibitors have the potential to be selectively toxic for BRCA-mutated cells. In addition to catalytic inhibition, it has been shown that some PARP inhibitors induce PARP trapping at sites of DNA damage. The capacity to trap PARP-DNA complexes varies widely across different PARP inhibitors and is not correlated with PARP catalytic inhibition. Preclinical models have shown trapping PARP on DNA is more potent at inducing cancer cell death than enzymatic inhibition of PARP alone. Talazoparib is a dual-mechanism PARP inhibitor that both inhibits the PARP enzyme and effectively traps PARP on DNA, preventing DNA damage repair and resulting in cell death in BRCA1/2-mutated cells. In preclinical studies, talazoparib at nanomolar concentrations showed the highest efficiency at trapping PARP-DNA complexes relative to other PARP inhibitors. In a previous phase 1/2 clinical study, talazoparib as monotherapy (1 mg once daily) resulted in a 50% response rate and an 86% clinical benefit rate at 24 weeks in 14 patients with a germline BRCA1/2 mutation and advanced breast cancer (aBC).
Methods: This open-label, randomized, 2-arm, international phase 3 trial (EMBRACA)
compares the efficacy and safety of talazoparib with protocol-specific physician's choice (capecitabine, eribulin, gemcitabine or vinorelbine) in patients with aBC. The primary objective is progression-free survival by central imaging. Secondary objectives are objective response rate, overall survival, safety and pharmacokinetics of talazoparib. Exploratory objectives include health-related quality of life measurements and biomarker research in blood and tumor samples that may permit characterization of mechanisms involved in tumor sensitivity and resistance to talazoparib. Key patient eligibility criteria include aged ≥18 years with histologically/cytologically confirmed breast cancer; locally advanced and/or metastatic disease appropriate for systemic single-agent cytotoxic chemotherapy; deleterious or pathogenic germline BRCA1/2 mutations by central laboratory; ≤3 prior cytotoxic chemotherapy regimens for advanced disease (prior platinum is allowed provided patients did not relapse within 6 months in the adjuvant setting or did not progress on platinum therapy); prior treatment with a taxane and/or anthracycline unless medically contraindicated; and ECOG performance status ≤2. Patients (N=429) will be randomized 2:1 to receive either talazoparib capsules (1 mg/day, 21-day cycles) or physician's choice treatment. This trial is currently enrolling patients from the USA, Europe, Israel, Ukraine, Russia, Korea, Australia, Taiwan and Brazil (NCT01945775).
This study is funded by Medivation, Inc.
Citation Format: Litton J, Ettl J, Hurvitz SA, Mina LA, Rugo HS, Lee K-H, Yerushalmi R, Woodward N, Goncalves A, Moreno F, Roche H, Im Y-H, Martin M, Bhattacharya S, Peterson A, Hannah A, Eiermann W, Blum J. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-13.
Collapse
Affiliation(s)
- J Litton
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - J Ettl
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - SA Hurvitz
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - LA Mina
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - HS Rugo
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - K-H Lee
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - R Yerushalmi
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - N Woodward
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Goncalves
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - F Moreno
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - H Roche
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - Y-H Im
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - M Martin
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - S Bhattacharya
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Peterson
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Hannah
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - W Eiermann
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - J Blum
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| |
Collapse
|
38
|
Litton JK, Blum JL, Im YH, Martin M, Mina LA, Roche HH, Rugo HS, Visco F, Zhang C, Lokker NA, Lounsbury DL, Eiermann W. A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.tps1107] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain
| | | | | | - Hope S. Rugo
- University of California, San Francisco, San Francisco, CA
| | - Fran Visco
- Natl Breast Cancer Coalition, Washington, DC
| | | | | | | | | |
Collapse
|
39
|
Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Byers LA, Chugh R, Goldman JW, Sachdev JC, Matei DE, Wheler JJ, Henshaw JW, Zhang C, Gallant G, De Bono JS. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.7522] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- Zev A. Wainberg
- David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
| | - Saeed Rafii
- The Royal Marsden Hospital, Sutton, United Kingdom
| | | | | | | | | | - Jonathan Wade Goldman
- David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
| | - Jasgit C. Sachdev
- TGen - Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ
| | | | | | | | | | | | | |
Collapse
|
40
|
Mina LA, Ramanathan RK, Wainberg ZA, Byers LA, Chugh R, Sachdev JC, Matei D, Zhang C, Henshaw JW, Dorr A, Kaye SB, de Bono JS. Abstract P2-09-02: BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-09-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BMN 673 is the most potent and specific inhibitor of poly-ADP ribose polymerase (PARP) 1 and 2 in clinical development (IC50<1nM). In BRCA-related tumors, which are genetically dependent on PARP-mediated DNA repair by base excision repair, PARP inhibition induces synthetic lethality. Initial phase 1 results have been presented (de Bono et al JCO 31:5s, 2013 suppl; abstr 2580), showing good tolerability and anti-tumor activity with an MTD on a daily, oral dosing schedule of 1000 μ/day.
Methods: In this 2-stage study, patients with solid tumors including BRCA-related cancers, were enrolled during dose-escalation followed by an expansion phase at the MTD in breast, ovarian, and pancreatic cancer patients with deleterious germline BRCA mutations and in small cell lung cancer and Ewing sarcoma patients to further characterize safety and efficacy. This abstract summarizes demographics and safety for all patients and efficacy for patients with BRCA-related cancers.
Results: As of 17May2013, a total of 1 pancreatic, 18 breast (17F/1M), and 28 ovarian cancer pts with germline BRCA mutations were enrolled at doses from 100-1100 μg/day. All breast cancer patients were treated from 900-1100 μg/day. The median (range) age for all 70 patients is 51.5 (18-81), PS 0 (0-1) and # of prior therapies 4 (1-13), with 47 patients having deleterious BRCA mutations. An MTD of 1000 μg/day was established with thrombocytopenia being dose-limiting. Related adverse events occurring in > 10% of all 70 patients included fatigue, nausea, alopecia, anemia, thrombocytopenia and neutropenia. One patient has had related grade 4 thrombocytopenia. Grade 3 related AE's included fatigue in 1 patient (1%), anemia and thrombocytopenia in 9 each (13%) and neutropenia in 4 (6%). Dose reductions occurred in 11 pts due to myelosuppression. No patients discontinued for adverse events.
Response in Germline BRCA PatientsBRCA Tumor TypeNDose Range (μ/day)ResponseBreast18900-11001CR/6PR/5SD≥12 weeksOvarian28100-11001CR/10PR/19GCIG/4SD≥24 weeksPancreas110001 SD ≥ 12weeksTwo of 2 BRCA breast responders had responded to prior platinum while 0 of 4 non-responders to prior platinum responded to BMN 673. Five of 12 breast cancer pts with no prior platinum have responded.
Conclusions: BMN 673 is well tolerated with impressive anti-tumor activity in pts with deleterious germ line BRCA mutations. Myelosuppression and fatigue are the primary side effects associated with need for dose reduction. A phase 3 trial in metastatic breast cancer patients with deleterious germ line BRCA mutations is planned with single-agent, once-daily oral dosing of 1000 μg (1 mg) per day.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-02.
Collapse
Affiliation(s)
- LA Mina
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - RK Ramanathan
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - ZA Wainberg
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - LA Byers
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - R Chugh
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - JC Sachdev
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - D Matei
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - C Zhang
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - JW Henshaw
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - A Dorr
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - SB Kaye
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | - JS de Bono
- Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| |
Collapse
|
41
|
Henshaw JW, Zhou H, Herriott A, Patterson M, Wang EW, Musson D, de Bono J, Mina LA, Ramanathan RK, O'Neill C, Dorr A, Curtin NJ. Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-a220] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: BMN 673 is a novel, potent (IC50 < 1.0 nM) inhibitor of Poly(ADP-ribose) polymerase (PARP) 1 and PARP 2 in clinical development for the treatment of genetically defined cancers.
Methods: The pharmacokinetics (PK) and pharmacodynamics (PD) of BMN 673 were evaluated in a Phase 1 dose-escalation study in patients with advanced solid tumors. Oral doses evaluated ranged from 0.025 to 1.1 mg/day, with 3-6 patients evaluated at each dose level in a standard 3+3 design. The first dose in Cycle 1 was followed for 7 days without dosing for collection of serial PK and PD samples. Thereafter BMN 673 was administered once daily on Days 8 to 35, with predose PK and PD samples collected on Days 15 and 22. Following the last dose in Cycle 1 on Day 35, serial PK and PD samples were collected for 7 and 3 days, respectively, without dosing. In subsequent cycles, BMN 673 was administered daily in contiguous 28-day cycles. The PD activity of BMN 673 was measured in peripheral blood mononuclear cells (PBMCs) using assay methods previously described (Clin Cancer Res 2008 14:7917023, Biochem J 2011 436:671-679). Correlations between systemic BMN 673 exposure and inhibition of PBMC PARP activity were investigated across dose levels.
Results: BMN 673 demonstrated good oral bioavailability and a long half-life supporting daily dosing (ASCO 2013 Abstract 2580). While variable across and within patients, overall PBMC PARP activity decreased in a dose-dependent manner. Within individual patients at higher dose levels, PBMC PARP activity decreased soon after the first dose of BMN 673, and activity remained at suppressed levels with daily dosing. PBMC PARP activity rebounded when dosing was stopped, indicating the return of PARP function. Correlations between the mean percent baseline PARP activity with daily BMN 673 dosing and measures of steady-state BMN 673 exposures within individuals (i.e., Day 35 Cmin, Cmax, and AUC0-24) showed decreased PARP activity with increasing exposure. This correlation was well described using an Imax model with IC50 values based on an interim analyses of 1140 pg/mL, 3090 pg/mL, and 26700 pg-hr/mL for Cmin, Cmax, and AUC0-24, respectively.
Conclusions: PBMC PARP activity was rapidly and continuously inhibited with daily dosing of BMN 673. A positive correlation between systemic BMN 673 exposure and inhibition of PARP activity in PBMCs was demonstrated. This effect on a relevant pharmacodynamic marker provides in vivo proof of an on-target effect of BMN 673 and may be an initial step with potential to inform BMN 673 dose selection.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A220.
Citation Format: Joshua W. Henshaw, Huiyu Zhou, Ashleigh Herriott, Miranda Patterson, Evelyn W. Wang, Don Musson, Johann de Bono, Lida A. Mina, Ramesh K. Ramanathan, Charles O'Neill, Andrew Dorr, Nicola J. Curtin. Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A220.
Collapse
Affiliation(s)
| | - Huiyu Zhou
- 1BioMarin Pharmaceutical Inc., Novato, CA
| | | | | | | | - Don Musson
- 1BioMarin Pharmaceutical Inc., Novato, CA
| | - Johann de Bono
- 3Institiue of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | | | | | | | | |
Collapse
|
42
|
De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS, Ong M, Basu B, Wainberg ZA, Byers LA, Chugh R, Dorr A, Kaye SB, Ramanathan RK. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.2580] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2580 Background: BMN 673 is the most potent and specific inhibitor of PARP1/2 in clinical development (IC50<1nM). In tumors genetically dependent on DNA repair by homologous recombination PARP inhibition induces synthetic lethality. Methods: Pharmacokinetics (PK), pharmacodynamics (PD), safety and anti-tumor activity of BMN 673 were evaluated in a 2-stage dose-escalation study with 3-6 patients (pts)/dose level. In dose escalation (Stage 1) cycle 1 was 6 wks, with drug taken on days 1 and 8-35, for PK and PD assays, followed by daily continuous dosing in 4-wk cycles. Stage 2 (expansion at MTD) recruits pts with tumors defective in DNA repair: Ewing sarcoma, small cell lung cancer or tumors associated with BRCA mutation (mut). Results: 39 pts (33F/6M) were enrolled in 9 cohorts from 25 to 1100 µg/d that defined a MTD of 1000 µg/d. Median (range) age was 58 (19-81), PS 0 (0-1) and # of prior therapies 4 (1-13). Tumors (# with deleterious BRCA 1/2 mut) included 23 ovarian/primary peritoneal (17); 8 breast (6); 3 pancreas; 2 colon; 1 prostate (1), and 1 mullerian carcinosarcoma. 17 and 8 pts had BRCA 1 and 2 mut, respectively. Dose-limiting thrombocytopenia occurred in 1/6 and 2/5 pts at 900 and 1100 µg/d, respectively. Potentially-related adverse events in >10% of pts (# grade 1 and 2/grade 3 and 4) included fatigue (10/0); nausea (10/0); flatulence (4/0); anemia (5/2); neutropenia (4/3); thrombocytopenia (1/3); and grade 1 alopecia (10). Inhibition of PARP activity in PBMCs was observed at doses ≥ 100 µg/d. BMN 673 plasma concentrations peaked 1-2 hrs post-dose; exposure increased dose proportionally. Steady state plasma concentrations were reached by the end of the 2nd week of daily dosing; mean Cmax: 0.30 - 25.4 ng/mL and AUC0-24: 3.96 - 203 ng-hr/mL across the 25 to 1100 µg/d dose range after 28d of daily dosing. RECIST and/or CA-125 responses occurred at doses ≥ 100 µg/d in 11/17 BRCA carrier ovarian/peritoneal cancer pts. Objective responses occurred in 2/6 BRCA-carrier breast cancer pts. Conclusions: BMN 673 is well tolerated with impressive anti-tumor activity in pts with BRCA mut with a single agent recommended Phase II trial dose of 1000 µg/d due to dose-limiting thrombocytopenia. Clinical trial information: NCT01286987.
Collapse
Affiliation(s)
- Johann Sebastian De Bono
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | - Michael Gonzalez
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Nicola J. Curtin
- Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, United Kingdom
| | | | | | - Manpreet Chadha
- Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ
| | - Jasgit C. Sachdev
- Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ
| | - Daniela Matei
- Indiana University School of Medicine, Indianapolis, IN
| | - Gayle S. Jameson
- Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ
| | - Michael Ong
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Bristi Basu
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Zev A. Wainberg
- David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
| | | | | | | | - Stanley B. Kaye
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Ramesh K. Ramanathan
- Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare/TGen, Scottsdale, AZ
| |
Collapse
|
43
|
Mina LA, Gokmen-Polar Y, Goswami C, Storniolo AM, Li L, Badve S, Sledge GW. P2-13-01: Gene Profiling of Whole Blood May Identify Patients with BRCA Mutations. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The BRCA1 and the BRCA2 proteins play a role in DNA repair and confer genomic stability to the cell. Identifying BRCA mutation carriers has become an important tool for prevention as well as guiding therapy in cancer patients. We proposed to test the hypothesis that gene expression analysis of peripheral whole blood can reliably detect these mutations.
Materials and methods: Following IRB approval, 10cc of blood was collected from 36 women (BRCA1 (n=8), BRCA2 (n=9), Hereditary breast cancer without BRCA (FAM) (n=7), sporadic breast cancer (SPO) (n=11)). 3 of BRCA1 and 5 of BRCA2 samples were from women without cancer. Following RNA extraction (using the method described by Beekman et al) and quality assessment, Illumina® Whole-Genome DASL™ microarray (Human Ref-8 BeadChips) analysis was performed. The raw data was normalized and analyzed using Partek® Genomic Suite. Differentially expressed genes were identified using ANOVA analysis. Geneset specific supervised analysis was performed to visualize the inherent similarities and differences in the gene expression amongst different groups for 1) DNA repair and 2) Immune-system-related genes. Ingenuity Pathway Analysis (IPA) was performed to interpret the data in the context of biological processes, pathways and networks.
Results: Twenty-nine of the 87 immune-related genes were up-regulated in BRCA1 and BRCA2 groups compared to SPO or FAM groups; these included IL7R, CD53, CD2, CD48 and HLA-DRA. Twenty-five of the 79 DNA repair genes were up-regulated in BRCA1 and BRCA2; these included FANCC, RAD51L3, MSH2, MSH6 and PCNA. In IPA analysis, the comparison of BRCA1 vs. REST (BRCA2 + FAM + SPO) showed a strong immunologic signal, with the top altered biological processes including “Immunologic disease”, “Infection mechanism”, “Immune cell trafficking” and “cell-mediated immune response “. The top 5 canonical pathways also reflected a similar pattern and included “iCOS-iCOSL Signaling in T Helper Cells”, “OX40 Signaling Pathway”, “Calcium-induced T Lymphocyte”, “Apoptosis Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes” and “Protein Ubiquitination Pathway”. When BRCA2 was compared with the REST (BRCA1 + FAM + SPO), a much weaker signal was noted with none of the canonical pathways being significantly altered. PAM analysis showed that a set of 16 genes could differentiate the BRCA patients from the rest with an error rate of 5%. Further validation of this geneset is being performed.
Conclusion: Gene profiling in whole blood may offer an easy, reliable and inexpensive way to identify patients with BRCA mutation. Further studies are currently underway to validate our results in a larger patient population.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-13-01.
Collapse
Affiliation(s)
- LA Mina
- 1Indiana University School of Medicine, Indianapolis, IN
| | - Y Gokmen-Polar
- 1Indiana University School of Medicine, Indianapolis, IN
| | - C Goswami
- 1Indiana University School of Medicine, Indianapolis, IN
| | - AM Storniolo
- 1Indiana University School of Medicine, Indianapolis, IN
| | - L Li
- 1Indiana University School of Medicine, Indianapolis, IN
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN
| | - GW Sledge
- 1Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
44
|
Abstract
Metastasis is the leading cause of cancer death. The metastatic cascade is a complex yet inefficient process that we have only begun to understand in recent years. Several of the early steps of this cascade are not readily targetable in the clinic. Past therapeutic developmental strategies have not distinguished between micrometastases and overt metastases. This lack of understanding is apparent in therapies that have been developed for patients with metastatic disease that are not efficacious in patients with micrometastatic disease; that is, in the adjuvant setting. Moreover, drugs that target distant metastases often do not work in the adjuvant setting. This Review will discuss our current understanding of the metastatic cascade as it relates to therapy, emerging therapeutic targets in the metastatic process, and how novel antimetastatic therapies might be developed for clinical use.
Collapse
Affiliation(s)
- Lida A Mina
- Department of Hematology/Oncology, Indiana University Simon Cancer Center, Indiana Cancer Pavilion, Indianapolis, IN 46202, USA.
| | | |
Collapse
|